<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 10-K
------------
(Mark One) Annual Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934 [Fee Required]
[X]
For the Fiscal Year Ended September 30, 1999
OR
[_] Transition Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 [No Fee Required]
For the transition period from to
Commission Registrant, State of Incorporation IRS Employer
File Number Address and Telephone Number Identification No.
----------- ---------------------------------- ------------------
33-27835-01 AmeriSource Health Corporation 23-2546940
(a Delaware Corporation)
300 Chester Field Parkway
Malvern, PA 19355
(610) 296-4480
Securities Registered Pursuant to
Section 12(b) of the Act: AmeriSource Health Corporation: NONE
Securities Registered Pursuant to
Section 12(g) of the Act: AmeriSource Health Corporation: COMMON
STOCK, $.01 PAR VALUE PER SHARE
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes [X] No [_]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [_]
Non-affiliates of AmeriSource Health Corporation, as of December 1, 1999, held
49,092,588 shares of voting stock. The registrant's voting stock is traded on
the New York Stock Exchange under the trading symbol "AAS." The aggregate
market value of the registrant's voting stock held by non-affiliates of the
registrant (based upon the closing price of such stock on the New York Stock
Exchange on December 1, 1999 and the assumption for this computation only that
399 Venture Partners, Inc. and all directors and executive officers of the
registrant are affiliates) was $610,589,063.25.
The number of shares of common stock of AmeriSource Health Corporation
outstanding as of December 1, 1999 was: Class A--51,178,274; Class B--8,446;
Class C--165,346.
Documents Incorporated by Reference
Portions of the following document are incorporated by reference in the Part
of this report indicated below:
Part III--Registrant's Proxy Statement for the 2000 Annual Meeting of
Stockholders.
<PAGE>
PART I
Item 1. Business
AmeriSource Health Corporation, through its direct wholly-owned subsidiary
AmeriSource Corporation (referred to collectively as "AmeriSource" and the
"Company"), is the fourth largest full-service wholesale distributor of
pharmaceutical products and related health care services in the United States.
The Company serves its customers nationwide through 22 drug distribution
facilities and three specialty products distribution facilities. AmeriSource
is typically the primary source of supply to its customers and offers a broad
range of services designed to enhance the operating efficiencies and the
competitive positions of its customers and suppliers. The Company benefits
from a diverse customer base that includes hospitals and managed care
facilities (48%), independent community pharmacies (39%) and chain drug
stores, including pharmacy departments of supermarkets and mass merchandisers
(13%).
Over the past five years, AmeriSource has achieved significant growth in
revenues and operating income before unusual items. The Company's operating
revenues have increased from $4.3 billion in fiscal 1994 to $9.8 billion in
fiscal 1999, a compound annual growth rate of 17.8%, while operating income
before unusual items and amortization increased from $86.3 million in fiscal
1994 to $175.9 million in fiscal 1999, a compound annual growth rate of 15.3%.
The Company's growth is primarily the result of overall industry growth,
market share gains in existing markets, acquisitions, and geographic
expansion.
AmeriSource Health Corporation was incorporated in Delaware in 1988. The
address of the principal executive office of the Company is 300 Chester Field
Parkway, Malvern, PA 19355. The telephone number is (610) 296-4480.
Business Strategy
Over the past five years, AmeriSource has significantly expanded its
national presence as a leading, innovative wholesale distributor of
pharmaceutical products and related health care services. The Company believes
it is well-positioned to continue its revenue growth and increase operating
income by providing solutions and services to its existing and potential
customers and through the execution of the following key elements of its
business strategy:
. Increasing Market Share in Existing Markets. The Company believes that it
is well-positioned to continue to grow in its existing markets by: (i)
providing superior distribution services coupled with advanced
information systems to reduce costs throughout the pharmaceutical supply
channel; (ii) continuing to develop or acquire specialty value-added
services and programs, including internet based services and programs, to
improve the competitiveness of its customers and suppliers; (iii)
continuing to expand geographically by further penetrating select market
areas where the Company has in the last few years opened distribution
centers or acquired other distributors; (iv) maintaining its low-cost
operating structure to ensure that the Company's services are priced
competitively in the marketplace; and (v) continuing its decentralized
operating structure to respond to customers' needs more quickly and
efficiently and to ensure the continued development of local and regional
management talent. These factors have allowed AmeriSource to compete
effectively in the marketplace and generate above-average industry sales
growth over the last five years.
. Continuing Growth of Specialty Services. The Company works closely with
both customers and suppliers to develop an extensive range of specialty
services. In addition to enhancing the Company's profitability, these
services increase customer loyalty and strengthen the Company's overall
role in the pharmaceutical supply channel. These services include:
ECHO(R), a proprietary software system providing sophisticated ordering
and inventory management assistance to hospital and retail customers;
Family Pharmacy(R), which enables small chain and independent community
pharmacies to compete more effectively through access to disease
management and pharmaceutical care programs, pharmaceutical benefit
programs and merchandising programs, as well as the internet; Income
Rx(R) and AmeriSource Select(R), providing an integral value-added
service to retail and hospital pharmacy customers by continually
reviewing the marketplace for generic products that offer the best price,
quality and availability; American Health
1
<PAGE>
Packaging, the Company's state-of-the-art packaging facility in Columbus,
Ohio; MedAssesstm, the Company's innovative patient care program designed
to help pharmacies generate new patient care revenue by providing
specialized services such as continuing education, self-directed training,
and the MedAssesstm patient care software; The Diabetes Shoppe, which
develops pharmacy-based diabetes care centers to market over 600
specialized products and training for the diabetes patient; and Health
Services Plus(R), which distributes vaccines, injectables, plasma and
oncology products to alternate care sites such as clinics, physicians, and
surgery centers. Many of the above services, including ECHO(R) and Family
Pharmacy(R) are in the process of being modified to include an internet
platform to enable the Company's customers to participate in the evolving
internet-based pharmacy business. In addition, the Company has purchased a
19.9% interest in ADDS, Inc., a leading provider of e-commerce medications
management solutions for the healthcare industry.
. Acquisition Opportunities. The Company believes that opportunities may
arise to acquire local and regional drug wholesale companies or other
companies or product lines which will complement its existing business.
. Maintain Low-Cost Operating Structure. AmeriSource believes it has one of
the lowest operating cost structures among its four major national
competitors. Over the past five years, the Company has significantly
reduced operating expenses as a percentage of revenues. Specifically, the
Company has reduced its selling and administrative expenses and
depreciation as a percentage of operating revenues from 3.60% in fiscal
1994 to 3.04% in fiscal 1999. In addition, the Company continues to
achieve productivity and operating income gains from continued
investments in advanced management information systems, centralizing
selected support functions, warehouse automation technology, and
operating leverage due to increased volume per Rx distribution facility.
The addition of new facilities was accomplished with minimal incremental
investment in corporate overhead. As these facilities continue to expand
in their regional markets, the Company believes that its growth and
profitability will be further enhanced.
Industry Overview
The Company has benefited from the significant growth of the full-service
drug wholesale industry in the United States. Industry sales grew from $30
billion in 1990 to $77 billion in 1998. The factors contributing to this
growth, and the sources of future growth for the industry, include (i) an aging
population, (ii) the introduction of new pharmaceuticals, (iii) the increased
use of outpatient drug therapies, and (iv) rising pharmaceutical prices.
Aging Population. The number of individuals over age 65 in the United States
grew 22% from approximately 26 million in 1980 to approximately 31 million in
1990 and is projected to increase an additional 12% to more than 35 million by
the year 2000. This age group suffers from a greater incidence of chronic
illnesses and disabilities than the rest of the population and is estimated to
account for approximately two-thirds of total health care expenditures in the
United States.
Introduction of New Pharmaceuticals. Traditional research and development as
well as the advent of new research, production and delivery methods, such as
biotechnology and gene research and therapy, continue to generate new compounds
and delivery methods that are more effective in treating diseases. These
compounds have been responsible for significant increases in pharmaceutical
sales. The Company believes that ongoing research and development expenditures
by the leading pharmaceutical manufacturers will contribute to continued growth
of the industry.
Cost Containment Efforts. In response to rising health care costs,
governmental and private payors have adopted cost containment measures that
encourage the use of efficient drug therapies to prevent or treat diseases.
While national attention has been focused on the overall increase in aggregate
health care costs, the Company believes drug therapy has had a beneficial
impact on overall health care costs by reducing expensive surgeries
2
<PAGE>
and prolonged hospital stays. Pharmaceuticals currently account for less than
11% of overall health care costs, and manufacturers' emphasis on research and
development is expected to continue the introduction of cost-effective drug
therapies.
Pharmaceutical Price Increases By Drug Manufacturers. The Company believes
that price increases by pharmaceutical manufacturers will continue to equal or
exceed the overall Consumer Price Index. The Company believes that these
increases will be due in large part to the relatively inelastic demand in the
face of higher prices charged for patented drugs as manufacturers have
attempted to recoup costs associated with the development, clinical testing
and Food and Drug Administration ("FDA") approval of new products.
At the same time that sales through the wholesale drug industry have grown,
the number of pharmaceutical wholesalers in the United States has decreased
from 139 at the end of 1980 to approximately 42 as of September 1999. Industry
analysts expect this consolidation trend to continue, with the industry's
largest companies increasing their percentage of total industry sales.
Operations
Decentralized Operating Structure. The Company believes that operating
economies of scale exist principally at the distribution facility level.
AmeriSource currently operates 22 drug distribution facilities and three
specialty products distribution facilities, organized into five regions across
the United States. Unlike its more centralized competitors, the Company is
structured as an organization of locally managed profit centers. Management of
each distribution facility has responsibility for its own financial
performance. The distribution facility's results, including earnings and
achievement of asset management goals, have a direct impact on management
compensation at these facilities. The distribution facilities utilize the
Company's corporate staff for marketing, financial, purchasing, legal and
executive management resources and corporate coordination of asset and working
capital management. In the fourth quarter of fiscal 1998, the Company began to
centralize its data processing, accounting, and contract administration and
purchasing functions. As of December 1999, 18 drug distribution facilities
have been centralized. The Company believes that the centralization of these
administrative functions will result in future efficiencies without affecting
the Company's decentralized operations and management.
Sales and Marketing. The Company has an organization of over 215 sales
professionals organized regionally and specialized by customer class. Customer
service representatives are located in each distribution facility in order to
respond to customer needs in a timely and effective manner. In addition, a
specially trained group of telemarketing representatives makes regular contact
with customers regarding special promotions. The Company's corporate marketing
department designs and develops the Company's array of value-added programs
and works with manufacturer suppliers to develop national promotions. Tailored
to specific customer classes, these programs can be further customized at the
distribution facility level to adapt to local market conditions. The marketing
department gathers and disseminates information to each operating unit in
order to enhance its competitive effectiveness.
Facilities. Each of the Company's distribution facilities carries an
inventory line necessary for its local market. The efficient distribution of
small orders is possible through the extensive use of computerization and
modern warehouse techniques. These include computerized warehouse product
location, routing and inventory replenishment systems, gravity-flow racking,
mechanized order selection and efficient truck loading and routing. The
Company typically delivers its products to its customers on a daily basis. It
utilizes a fleet of owned and leased vans and trucks and contract carriers.
Night picking operations in its distribution facilities have further reduced
delivery time. Orders are generally delivered in less than 24 hours.
3
<PAGE>
The following table presents certain information on a fiscal year basis
regarding the Company's operating units in the aggregate.
<TABLE>
<CAPTION>
Fiscal Year Ended September 30,
--------------------------------------------
1995 1996 1997 1998 1999
-------- -------- -------- -------- --------
(dollars in millions; square feet in
thousands)
<S> <C> <C> <C> <C> <C>
Operating revenue................. $4,876.3 $5,806.1 $8,173.7 $9,373.5 $9,760.1
Number of Rx distribution
facilities....................... 19 21 22 23 22
Average revenue/Rx distribution
facility......................... $ 255.1 $ 274.6 $ 366.9 $ 398.8 $ 432.4
Total square feet (Rx facilities). 1,519.1 1,889.7 2,318.1 2,286.0 2,174.4
Average revenue/square foot (in
whole dollars) (Rx facilities)... $ 3,191 $ 3,052 $ 3,482 $ 4,012 $ 4,375
</TABLE>
Customers and Markets. The Company has a diverse customer base that includes
hospitals and managed care facilities, independent community pharmacies and
chain drug stores, including pharmacy departments of supermarkets and mass
merchandisers. The Company offers a broad range of services designed to
enhance the operating efficiencies and competitive positions of its customers
and suppliers. In addition, AmeriSource is typically the primary source of
supply for its customers. The table below summarizes how the Company's
customer sales mix has changed over the last five fiscal years.
<TABLE>
<CAPTION>
Fiscal Year Ended September 30,
-----------------------------------------------------------
1995 1996 1997 1998 1999
----------- ----------- ----------- ----------- -----------
(dollars in millions)
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Hospitals and Managed
Care Facilities........ $2,422 50% $2,675 46% $3,710 45% $4,200 45% $4,650 48%
Independents............ 1,601 33% 2,057 35% 2,929 36% 3,567 38% 3,855 39%
Chains.................. 853 17% 1,074 19% 1,535 19% 1,606 17% 1,255 13%
------ ---- ------ ---- ------ ---- ------ ---- ------ ----
Total operating
revenue............. $4,876 100% $5,806 100% $8,174 100% $9,373 100% $9,760 100%
====== ==== ====== ==== ====== ==== ====== ==== ====== ====
</TABLE>
No single customer represented more than 5% of the Company's total operating
revenues during fiscal 1999, except for the federal government, which
accounted for approximately 18%. Excluding the federal government, the
Company's top ten customers represented approximately 9% of total operating
revenues during fiscal 1999. A profile of each customer class follows:
. Hospitals and Managed Care Facilities. AmeriSource is one of the nation's
top distributors in serving the hospital and managed care market. Because
hospitals and managed care facilities purchase large volumes of high-
priced, easily handled pharmaceuticals, the Company benefits from quick
turnover of both inventory and receivables and lower-than average
operating expenses. Sales to hospitals and managed care facilities have
grown at a compound rate of 17.7% from fiscal 1995 through fiscal 1999.
. Independents. Independent community pharmacy owners provide the greatest
opportunity for the Company's value-added services. The Company's sales
to independent customers have risen at a compound rate of 24.6% from
fiscal 1995 through fiscal 1999 due to the general growth within this
customer class, the Company's recent acquisition activity, and the
success of the Company's customized marketing and merchandising programs,
such as its Family Pharmacy(R) program.
. Chains. This class includes chain drug stores, including pharmacy
departments of supermarkets and mass merchandisers. The Company's sales
to chains have risen at a compound rate of 10.1% from fiscal 1995 through
fiscal 1999. This growth rate reflects new contracts with several retail
chains as well as the
growth of existing retail chain customers. However, sales to chain drug
stores decreased to 13% of operating revenue in fiscal 1999 due to the
termination of service contracts with two large warehousing drug chains in
fiscal 1998.
Suppliers. AmeriSource obtains pharmaceutical and other products from a
number of manufacturers, none of which accounted for more than approximately
8% of its net sales in fiscal 1999. The five largest suppliers in fiscal 1999
accounted for approximately 28% of net sales. Historically, the Company has
not experienced difficulty in purchasing desired products from suppliers. The
Company has agreements with many of its suppliers which generally require the
Company to maintain an adequate quantity of a supplier's products in
inventory.
4
<PAGE>
The majority of contracts with suppliers are terminable upon 30 days notice by
either party. The loss of certain suppliers could adversely affect the
Company's business if alternate sources of supply were unavailable. The
Company believes that its relationships with its suppliers are good.
Management Information Systems. The Company has continually invested in
advanced management information systems and automated warehouse technology.
The Company's management information systems provide for, among other things,
electronic order entry by customers, invoice preparation and purchasing and
inventory tracking. As a result of electronic order entry, the cost of
receiving and processing orders has not increased as rapidly as sales volume.
The Company's customized systems strengthen customer relationships by allowing
the customer to lower its operating costs and by providing the basis for a
number of the value-added services the Company provides to its customers,
including marketing data, inventory replenishment, single-source billing,
computer price updates and price labels. During 1999, the Company successfully
closed six data processing centers and converted 18 (including 3 in December
1999) pharmaceutical distribution facilities into one centralized management
information system. Three remaining pharmaceutical distribution facilities are
scheduled to be converted in fiscal 2000. This initiative allowed the Company
to improve its information capabilities and eliminate redundant processing and
computer operating expenditures. AmeriSource believes that its management
information systems are capable of serving its needs for the foreseeable
future.
Competition
The Company engages in the wholesale distribution of pharmaceuticals, health
and beauty aids and other products in a highly competitive environment. The
Company competes with numerous national and regional distributors, some of
which are larger and have greater financial resources than the Company. The
Company's national competitors include McKessonHBOC, Inc., Bergen Brunswig
Corporation, Cardinal Health, Inc., and Bindley Western Industries, Inc. In
addition, the Company competes with regional and local distributors, direct-
selling manufacturers, warehousing chain drug stores, and other specialty
distributors. Competitive factors include value-added service programs,
breadth of product line, price, service and delivery, credit terms and
customer support. There can be no assurance that the Company will not
encounter increased competition in the future that could adversely affect the
Company's business. The drug wholesale industry continues to undergo
significant consolidation, with the number of wholesalers in the continental
United States declining from 139 at the end of 1980 to approximately 42 as of
September 1999.
Employees
As of September 30, 1999, the Company employed approximately 3,600 persons,
of which approximately 3,400 were full-time employees. Approximately 12% of
full and part-time employees are covered by collective bargaining agreements.
The Company believes that its relationship with its employees is good.
Regulatory Matters
The United States Drug Enforcement Administration and the Food and Drug
Administration and various state boards of pharmacy regulate the distribution
of pharmaceutical products and controlled substances, requiring wholesale
distributors of these substances to register for permits and to meet various
security and operating standards. As a wholesale distributor of
pharmaceuticals and certain medical/surgical products, the Company is subject
to these regulations. The Company has received all necessary regulatory
approvals and believes that it is in substantial compliance with all
applicable wholesale distribution requirements.
The Company is aware that at its former Charleston, South Carolina
distribution center there is evidence of residual soil contamination remaining
from the fertilizer manufacturing process operated on that site by third
parties over thirty years ago. The Company's environmental consulting firm
conducted a soil survey and a groundwater study during fiscal 1994 and 1995.
The results of the studies indicate that there is lead on-site at levels
requiring further investigation and potential remediation. A preliminary
engineering analysis was prepared by outside consultants during the third
quarter of fiscal 1994, and indicated that, if both soil and groundwater
remediation are required, the most likely cost is estimated to be $4.1
million. Accordingly, a liability of $4.1 million was recorded during fiscal
1994 to cover future consulting, legal and remediation and ongoing monitoring
5
<PAGE>
costs. The Company is working with the appropriate state and federal
regulatory agencies regarding further tests and potential site remediation.
That negotiation, investigation and remediation could take several years and
the actual costs may differ from the liability that has been recorded. The
accrued liability ($3.8 million at September 30, 1999), which is reflected in
other liabilities in the Company's consolidated balance sheet, is based on the
present estimate of the extent of contamination, choice of remedy, and enacted
laws and regulations, including remedial standards; however, changes in any of
these could affect the estimated liability.
Acquisitions
In July 1999, the Company acquired C.D. Smith Healthcare, Inc. ("C.D.
Smith"), a regional wholesale pharmaceutical distributor based in St. Joseph,
Missouri. The Company exchanged approximately 2.44 million shares of its
common stock and .25 million common stock options for all of the outstanding
common stock and common stock options of C.D. Smith.
Item 2. Properties
As of September 1999, the Company conducted its business from office and
operating unit facilities at 40 locations throughout the United States. In the
aggregate, the Company's operating units occupy approximately 2.5 million
square feet of office and warehouse space, of which approximately 987,000
square feet is owned and the balance is leased under lease agreements with
expiration dates ranging from 1999 to 2012. The Company's 22 drug distribution
facilities range in size from approximately 20,000 square feet to 207,100
square feet. Leased facilities are located in the following states: Alabama,
Arizona, California, Delaware, Florida, Idaho, Indiana, Kentucky,
Massachusetts, Minnesota, New Jersey, Ohio, Oregon, Pennsylvania, Tennessee,
Texas, Virginia and West Virginia. Owned facilities are located in the
following states: Alabama, Illinois, Indiana, Kentucky, Maryland, Missouri,
Ohio, Tennessee and Virginia. The Company utilizes a fleet of owned and leased
vans and trucks, as well as contract carriers to deliver its products. The
Company believes that its properties are adequate to serve the Company's
current and anticipated needs without making capital expenditures materially
higher than historical levels.
Item 3. Legal Proceedings
In 1998 the Company sued a former customer which refused to pay invoices,
net of credit memos, totaling approximately $21 million for goods sold and
delivered. The former customer has filed counterclaims alleging it suffered
damages as a result of certain performance problems affecting the Company. The
Company believes there is no merit to these counterclaims and is aggressively
pursuing collection of the outstanding amount. A trial is scheduled for
January 2000 and ultimate collectibility of amounts owed to the Company is
dependent on the outcome of the trial and the continued creditworthiness of
the former customer.
In November 1993, the Company was named a defendant, along with six other
wholesale distributors and twenty-four pharmaceutical manufacturers, in a
series of purported class action antitrust lawsuits brought by retail
pharmacies and alleging violations of various antitrust laws stemming from the
use of chargeback agreements. In addition, the Company and four other
wholesale distributors were added as defendants in a series of related
antitrust lawsuits brought by independent pharmacies and chain drug stores,
both of which opted out of the class cases. The Company also was named a
defendant in parallel suits filed in state courts in Minnesota, Alabama,
Tennessee and Mississippi. The federal class actions were originally filed in
the United States District Court for the Southern District of New York, but
were transferred along with the individual and chain drug store cases to the
United States District Court for the Northern District of Illinois for
consolidated and coordinated pretrial proceedings. In essence, these lawsuits
all claim that the manufacturer and wholesaler defendants have combined,
contracted and conspired
to fix the prices charged to retail pharmacies for prescription brand name
pharmaceuticals. Specifically, plaintiffs claim that the defendants use
"chargeback agreements" to give some institutional pharmacies discounts that
allegedly are not made available to retail drug stores. Plaintiffs seek
injunctive relief, treble damages, attorneys' fees and costs. In October 1994,
the Company entered into a Judgment Sharing Agreement with the other
wholesaler and pharmaceutical manufacturer defendants. Under the Judgment
Sharing Agreement: (a) the manufacturer defendants agreed to reimburse the
wholesaler defendants for litigation costs incurred, up to an
6
<PAGE>
aggregate of $9 million; and (b) if a judgment is entered against both
manufacturers and wholesalers, the total exposure for joint and several
liability of the Company is limited to the lesser of 1% of such judgment or $1
million. In addition, the Company has released any claims which it might have
had against the manufacturers for the claims presented by the Plaintiffs in
these lawsuits. Subsequent amendments to the Judgment Sharing Agreement have
provided additional protection to the Company from litigation expenses in
exchange for updated releases. The Judgment Sharing Agreement covers the
federal court litigation as well as the cases which have been filed in various
state courts.
On April 4, 1996, the District Court granted the Company's motion for
summary judgment in the class case. Plaintiffs subsequently appealed the
Company's grant of summary judgment to the United States Seventh Circuit Court
of Appeals. On August 15, 1997, the Court of Appeals reversed the District
Court's order granting summary judgment in favor of the Company and the other
wholesalers. The Court of Appeals also denied the Company's petition for
rehearing. The Company and the other wholesalers filed a petition for a writ
of certiorari to the United States Supreme Court; the petition was denied.
Trial in the class case commenced in the United States District Court for the
Northern District of Illinois on September 23, 1998. After a ten-week trial,
the Court granted all of the defendants' motions for a directed verdict and
dismissed the claims the class plaintiffs had asserted against the Company and
the other wholesale distributors and the pharmaceutical manufacturers.
Plaintiffs in the class case then appealed the District Court's judgment to
the Seventh Circuit Court of Appeals. On June 9, 1999, the Seventh Circuit
affirmed the judgment the District Court entered in favor of the Company in
the class case. Plaintiffs have filed a petition for a writ of certiorari to
the United States Supreme Court; that petition is pending.
The state cases are proceeding. The Minnesota case settled without any
payment or admission of liability by the Company. On November 29, 1999, the
trial court in Alabama dismissed all of the claims asserted against the
Company and the other wholesaler and manufacturer defendants in accordance
with a ruling from the Alabama Supreme Court. The Mississippi and Tennessee
cases remain pending, though there has been very little activity in either
forum.
On or about October 2, 1997, a group of retail chain drug stores and
individual pharmacies, both of which had opted out of the class cases, filed a
motion with the United States District Court for the Northern District of
Illinois seeking to add the Company and the other wholesale distributors as
defendants in their cases against the manufacturer defendants, which cases are
consolidated before the same judge who presides over the class cases. This
motion was granted and the Company and the other wholesale distributors have
been added as defendants in those cases as well. As a result, the Company has
been served with approximately 120 additional complaints on behalf of
approximately 4,000 pharmacies and chain retailers. Discovery and motion
practice is presently underway in all of these opt-out cases. The Company
believes it has meritorious defenses to the claims asserted in these lawsuits
and intends to vigorously defend itself in all of these cases.
AmeriSource has been named as a defendant in four lawsuits based upon
alleged injuries attributable to a category of products typically referred to
as fen-phen. AmeriSource did not manufacture these products; however, prior to
an FDA recall, AmeriSource did distribute these products from several of its
vendors. The Company believes that it is entitled to full indemnification by
its vendors with respect to these lawsuits and any other lawsuits involving
these products in which AmeriSource may be named in the future. The Company
believes that its insurance coverage and indemnification rights are adequate
to cover any losses, if they should occur.
The Company is a party to various lawsuits arising in the ordinary course of
business; however, the Company does not believe that the outcome of these
lawsuits, individually or in the aggregate, will have a material adverse
effect on its business or financial condition. (See Note 11 to the
consolidated financial statements.)
Item 4. Submission of Matters to a Vote of Security Holders
During the fiscal quarter ended September 30, 1999, there were no matters
submitted to a vote of shareholders.
7
<PAGE>
Item 4a. Executive Officers of the Registrant
The following is a list of the Company's executive officers, their ages and
their positions, as of December 1, 1999. Each executive officer serves at the
pleasure of the Company's Board of Directors.
<TABLE>
<CAPTION>
Current Position with
the Company and Other Position Held in the last
Name Age Period of Service five years
---- --- ------------------------ ---------------------------------
<C> <C> <S> <C>
R. David Yost... 52 President and Chief Executive Vice President--
Executive Officer Operations (1995-1997);
(1997-Present) Group President--Central Region
(1989-1995)
Kurt J. 39 Senior Vice President Senior Vice President and Chief
Hilzinger...... and Chief Operating Financial Officer (1997-1999)
Officer (January 1999- Vice President, Chief Financial
Present) Officer and Treasurer (1995-
1997); Vice President, Finance
and Treasurer
(1993-1995).
David M. 52 Vice President, Executive Vice President--
Flowers........ AmeriSource Health Sales and Marketing (1995-1999)
Corporation and Group President--Eastern Region
President, American (1989-1995)
Health Packaging
(January 1999-Present)
George L. James, 53 Vice President and Chief Senior Vice President and Chief
III............ Financial Officer (May Financial Officer and other
1999-Present) positions, BetzDearborn, Inc.
(1995-1998); Vice President,
Corporate Development and
Planning and other various
positions, Scott Paper Company
(1977-1995)
</TABLE>
PART II
Item 5. Market for Registrants' Common Equity and Related Stockholder Matters.
Since May 27, 1996, the Company's Class A Common Stock has been traded on
the New York Stock Exchange under the trading symbol "AAS." Prior to May 27,
1996, the Company's Class A Common Stock was traded over-the-counter in the
National Market System of the National Association of Securities Dealers, Inc.
(Nasdaq symbol ASHC). As of December 1, 1999, there were 279 record holders of
the Company's Class A Common Stock. The following table sets forth the high
and low closing sale prices of the Class A Common Stock for the periods
indicated. Closing sale prices prior to March 3, 1999 have been restated for
the Company's two-for-one stock split on that date.
PRICE RANGE OF COMMON STOCK
<TABLE>
<CAPTION>
High Low
Year Ended 9/30/98 ---- ----
<S> <C> <C>
First Quarter............................................. $32 13/16 $26 13/16
Second Quarter............................................ 31 11/16 26 7/8
Third Quarter............................................. 32 27/32 25 1/2
Fourth Quarter............................................ 38 3/8 22 23/32
Year Ended 9/30/99
First Quarter............................................. 32 9/16 24 19/32
Second Quarter............................................ 40 17/32 33 3/4
Third Quarter............................................. 33 3/4 25
Fourth Quarter............................................ 28 13/16 23 1/16
</TABLE>
8
<PAGE>
There is no established public trading market for the Company's Class B
Common Stock. As of December 1, 1999, there were two record holders of the
Company's Class B Common Stock.
The Company's Class C Common Stock was held by two holders of record as of
December 1, 1999. The Class C Common Stock trades on a limited basis in the
over-the-counter market, and information concerning the historical trading
prices for the Class C Common Stock is not published by nationally-recognized
independent sources.
The Company has not paid any cash dividends to its stockholders on any class
of its Common Stock, and anticipates that for the foreseeable future its
earnings will be retained for use in its business. Payment of dividends is
within the discretion of the Company's Board of Directors and will depend,
among other factors, upon the Company's earnings, financial condition and
capital requirements and the terms of the Company's financing agreements, which
restrict the Company's ability to make dividend payments unless certain
financial tests are met.
Item 6. Selected Financial Data.
The following table should be read in conjunction with the Consolidated
Financial Statements, including the notes thereto, included elsewhere in this
report. All amounts have been restated to reflect the acquisition of C.D. Smith
in July, 1999 accounted for as a pooling-of-interests.
<TABLE>
<CAPTION>
Fiscal Year Ended September 30,
-------------------------------------------------------------------
1999(a) 1998(b) 1997(c) 1996 1995 1994(d)
---------- ---------- ---------- ---------- ---------- ----------
(amounts in thousands, except per share amounts)
<S> <C> <C> <C> <C> <C> <C>
Operating revenue............... $9,760,083 $9,373,482 $8,173,679 $5,806,126 $4,876,310 $4,308,351
Bulk deliveries to
customer warehouses............ 47,280 129,555 124,956 111,046 107,342 119,639
---------- ---------- ---------- ---------- ---------- ----------
Total revenue .................. 9,807,363 9,503,037 8,298,635 5,917,172 4,983,652 4,427,990
Gross profit.................... 473,065 461,897 404,136 314,489 275,758 241,574
Operating expenses,
excluding amortization......... 312,077 320,891 277,632 213,681 176,522 155,286
Operating income (loss)......... 159,002 138,931 125,445 100,507 99,059 (101,758)
Income (loss) before
extraordinary items and
in 1994 the cumulative
effect of accounting
changes........................ 70,915 46,030 50,123 43,463 28,256 (172,870)
Net income (loss) .............. 67,466 46,030 48,141 36,221 10,219 (208,124)
Earnings (loss) per
share--assuming
dilution:
Income (loss) before
extraordinary items
and in 1994 the
cumulative effect of
accounting changes............ 1.38 .91 1.00 .90 .71 (5.25)
Net income (loss) ............. 1.31 .91 .96 .75 .26 (6.33)
Weighted average common
shares outstanding--
assuming dilution (e)......... 51,683 50,713 50,301 48,376 40,029 32,899
Balance Sheet:
Cash and cash equiva-
lents and restricted
cash.......................... $ 59,497 $ 90,344 $ 71,551 $ 73,832 $ 46,995 $ 25,361
Accounts receivable--
net........................... 612,520 509,130 550,824 405,929 330,441 282,242
Merchandise inventories........ 1,243,153 954,010 1,046,582 677,173 423,942 365,835
Property and equipment--net.... $4,384 67,955 70,754 54,850 47,591 43,367
Total assets................... $2,060,599 $1,726,272 $1,798,109 $1,236,221 $ 872,979 $ 739,007
Accounts payable............... $1,175,619 $ 947,016 $1,070,673 $ 749,481 $ 483,180 $ 465,344
Long-term debt, less
current portion............... 558,705 539,464 601.454 443,690 446,182 496,749
Stockholders' equity........... 166,277 75,355 18,881 (34,856) (134,126) (299,165)
Total liabilities and
stockholders' equity.......... $2,060,599 $1,726,272 $1,798,109 $1,236,221 $ 872,979 $ 739,007
</TABLE>
(a) Includes the effect of $11.7 million of costs related to facility
consolidations and employee severance and $3.2 million of merger costs.
(b) Includes the effect of $18.4 million of merger costs and $8.3 million of
costs related to facility consolidations and employee severance.
(c) Includes the effect of $11.6 million of costs related to facility
consolidations and employee severance.
(d) Includes the effect of: the $179.8 million write-off of goodwill; the
cumulative effect of accounting changes for income taxes of $33.4 million;
and postretirement benefits other than pensions of $1.2 million.
(e) Share and per share amounts prior to March 1999 have been adjusted for the
two-for-one stock split effected in March 1999.
9
<PAGE>
Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations
AMERISOURCE HEALTH CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with the Consolidated
Financial Statements contained herein.
General
In July 1999, the Company acquired C.D. Smith Healthcare, Inc. ("C.D.
Smith"), a regional wholesaler headquartered in St. Joseph, Missouri, with
annual operating revenue of approximately $800 million. The Company exchanged
approximately 2.44 million shares of its common stock and .25 million common
stock options for all of the outstanding common stock and common stock options
of C.D. Smith. The business combination has been accounted for as a pooling-
of-interests and, accordingly, all results have been restated to reflect this
accounting treatment.
The Company's earnings per share and share data in the financial statements
have been restated to reflect the effect of a two-for-one stock split in March
1999.
Results of Operations
Year ended September 30, 1999 compared with Year ended September 30, 1998
Operating revenue for the fiscal year ended September 30, 1999 increased 4%
to $9.8 billion from $9.4 billion in fiscal 1998. During the fiscal year ended
September 30, 1999, sales to hospitals and managed care facilities increased
11%, sales to independent drug store customers increased 8%, and sales to the
chain drug store customer group decreased 22%, as compared with the prior
fiscal year. During the fiscal year ended September 30, 1999, sales to
hospitals and managed care facilities accounted for 48% of total operating
revenue, while sales to independent drug stores accounted for 39% and sales to
chain drug stores accounted for 13% of the total.
Revenue growth for fiscal 1999 was adversely affected by the termination of
service contracts with two large warehousing chains and one large mail order
customer during the third quarter of fiscal 1998. Two of these customers were
acquired by companies serviced by other pharmaceutical distributors. Excluding
the operating revenue in fiscal 1998 from these three customer losses,
operating revenue would have increased 12% in the fiscal year ended September
30, 1999 compared to September 30, 1998. Hospital sales, excluding managed
care facilities, increased 17% in fiscal 1999 over 1998, slightly over one-
half of which was growth in the government sector due to the Company's
expansion of its relationship with the Veterans Administration. The federal
government accounted for 18% of total operating revenue in fiscal 1999 versus
15% in fiscal 1998. The balance of the hospital growth was due to growth from
existing relationships with group purchasing organizations. Future operating
revenue may also be impacted by customer consolidation and competition in the
industry.
Along with other companies in its industry, the Company reports as revenue,
bulk shipments to customer warehouses, whereby the Company acts as an
intermediary in the ordering and subsequent delivery of pharmaceutical
products. Bulk shipments decreased 64% to $47.3 million in fiscal 1999
compared to fiscal 1998. Due to the insignificant service fees generated from
these bulk shipments, fluctuations in volume have no significant impact on
operating margins.
Gross profit of $473.1 million in fiscal 1999 increased by 2% compared to
fiscal 1998. As a percentage of operating revenue, the gross profit in fiscal
1999 was 4.85% as compared to 4.93% in the prior year. The decline was caused
by the shift in the customer mix as well as a reduction in selling margin due
to continued competition in the industry. Gross profit may continue to be
impacted by competition, changes in customer and product mix, and distribution
center performance.
10
<PAGE>
Selling and administrative expenses and depreciation increased by $3.0
million or 1% in fiscal 1999 compared to the prior fiscal year, and as a
percentage of operating revenue were 3.04% and 3.14% in fiscal 1999 and 1998,
respectively. The decrease as a percentage of operating revenue from the prior
year was due to the shift in customer mix away from warehousing chains,
resulting in decreases in warehouse and delivery expense compared to the prior
year, as well as continued productivity improvements from the Company's cost
reduction initiatives. These reductions combined with a reduction in bad debt
expense of $3.0 million offset costs incurred during the fiscal year ended
September 30, 1999 of $5.8 million related to the Company's centralization
process described below.
In connection with its acquisition of C.D. Smith, the Company incurred
merger costs of $3.2 million in the fourth quarter of fiscal 1999, consisting
primarily of investment banking, accounting and legal fees. In fiscal 1998,
the Company and McKessonHBOC jointly terminated a definitive merger agreement
signed in September 1997 after the Federal Trade Commission obtained an
injunction halting the proposed merger. Merger-related costs consisting of
professional fees and stay-put bonuses totaling $18.4 million were expensed in
the fourth quarter of fiscal 1998 as a result of the termination of the
McKessonHBOC merger agreement.
In connection with its acquisition of C.D. Smith, the Company began the
consolidation of C.D. Smith's Chicago, Illinois pharmaceutical distribution
facility into an existing AmeriSource distribution facility and the
consolidation of C.D. Smith's pharmaceutical packaging business into
AmeriSource's packaging operation. In addition, the Company began to
incorporate the remaining two C.D. Smith facilities into the centralization
process started in the fourth quarter of fiscal 1998. These efforts are
expected to be completed by the end of the second quarter of fiscal 2000 and
when complete are expected to provide annual cost savings of approximately $4
million to $6 million. A charge of $12.8 million was recognized in the fourth
quarter of fiscal 1999 related to this effort, and included a $7.2 million
write-down of goodwill and fixed assets related to the Chicago facility, $3.5
million of contract and lease cancellations and other costs primarily relating
to the expected termination costs of a non-cancellable supply contract, and
$2.1 million of severance for approximately 90 warehouse and administrative
personnel to be terminated as a result of the facility consolidation and
centralization. The write-down of goodwill represents the unamortized goodwill
specifically identified with the infrastructure of the Chicago facility. In
the fourth quarter of fiscal 1999, the Company also reversed $1.1 million of
costs originally accrued during fiscal 1997 for facility consolidations and
employee severance due to $0.8 million of proceeds in excess of estimates for
disposed assets and $0.3 million of severance settled for less than original
estimates.
In the fourth quarter of fiscal 1998, the Company began to centralize its
data processing, accounting, contract administration and purchasing functions,
reorganize its pharmaceutical distribution facilities into five regions and
consolidate one pharmaceutical distribution facility into another facility. A
charge of $8.3 million was recognized in the fourth quarter of fiscal 1998
related to this effort, and included severance of $3.3 million for
approximately 350 administrative and warehouse personnel and asset write-downs
and lease cancellation costs of $5.0 million, primarily consisting of owned
and leased data processing assets to be abandoned after the consolidation
dates of the affected data processing centers. As of September 30, 1999, 15 of
the original 19 targeted distribution facilities have been centralized. Three
more of the original facilities were centralized in December 1999 and the
remaining facility was rescheduled to be converted in the third quarter of
fiscal 2000 after the centralization of the two remaining C.D. Smith
facilities. As of September 30, 1999, 80 of the 350 targeted employees have
not yet been terminated.
Operating income of $159.0 million in fiscal 1999 increased by 14% from the
prior year. The Company's operating margin increased to 1.63% in fiscal 1999
from 1.48% in fiscal 1998 primarily due to the reduction in merger costs from
$18.4 million in fiscal 1998 to $3.2 million in fiscal 1999.
Interest expense of $39.4 million in fiscal 1999 represents a 22% decrease
from the prior year due to a combination of lower borrowing rates on its
variable-rate debt facilities as well as reduced average borrowings. Average
borrowing rates under the Company's variable-rate debt facilities declined
approximately 50 basis points from the prior fiscal year due to market
interest rate declines early in fiscal 1999 as well as the effect of a step-
down of 12.5 basis points achieved under the revolving credit facility and the
replacement of the Company's
11
<PAGE>
receivables securitization facility with a lower cost facility during the
fiscal year. In addition, the Company extinguished the higher rate C.D. Smith
debt with its variable-rate debt in the fourth quarter of fiscal 1999. LIBOR
rates have increased over 100 basis points since September 1999, which will
impact interest expense in fiscal 2000. Average borrowings decreased $89
million from $714 million in fiscal 1998 to $625 million in fiscal 1999 due
primarily to continued emphasis on asset management.
Interest expense-adjustment of common stock put warrant to fair value
declined to $0.3 million in fiscal 1999 from $7.8 million in fiscal 1998. The
fair value of the common stock put warrant was based on the value of the
underlying common stock of C.D. Smith prior to the merger with AmeriSource.
The warrant was exercised and converted into common stock in the fourth
quarter of fiscal 1999.
Income tax expense of $48.4 million in fiscal 1999 reflected an effective
tax rate of 40.6% versus 43.0% in the prior fiscal year. The reduction in the
effective rate was due to the reduction in the non-deductible interest
expense-adjustment of common stock put warrant to fair value described above.
Income before extraordinary items increased to $70.9 million in fiscal 1999
from $46.0 million in fiscal 1998. Income before extraordinary items per
share-assuming dilution increased to $1.38 in fiscal 1999, a 52% increase from
fiscal 1998 primarily due to the reduction in merger costs and interest
expense discussed above.
Extraordinary items-early retirement of debt of $3.4 million, net of income
tax benefits of $2.0 million, in fiscal 1999, relates to the extinguishment of
long-term debt assumed in the acquisition of C.D. Smith in the fourth quarter
of fiscal 1999 as well as the replacement of the Company's prior receivables
securitization facility with a new receivables securitization facility
described below.
Year ended September 30, 1998 compared with Year ended September 30, 1997
Operating revenue for the fiscal year ended September 30, 1998 increased 15%
to $9.4 billion from $8.2 billion in fiscal 1997. During the fiscal year ended
September 30, 1998, sales to hospitals and managed care facilities increased
13%, sales to independent drug store customers increased 22%, and sales to the
chain drug store customer group increased 5%, as compared with the prior year.
During the fiscal year ended September 30, 1998 sales to hospitals and managed
care facilities accounted for 45% of total operating revenue, while sales to
independent drug stores accounted for 38% and sales to chain drug stores
accounted for 17% of the total.
Approximately one-half of the operating revenue increase related to the
impact of the General Drug acquisition in October 1997 and the Walker Drug
Company, L.L.C. ("Walker Drug Company") acquisition in March 1997. The
internal rate of growth in fiscal 1998 was less than fiscal 1997 due to the
termination of service contracts with two warehousing chains and one large
mail order customer during the third fiscal quarter of 1998 that collectively
accounted for approximately $300 million of revenue per quarter. Sales to
chain drug stores decreased to 13% of operating revenue in the fourth quarter
of fiscal 1998 as a result of the service contract terminations.
Bulk shipments increased 4% in fiscal 1998 over fiscal 1997. Due to the
insignificant service fees generated from these bulk shipments, fluctuations
in volume have no significant impact on operating margins.
Gross profit of $461.9 million in fiscal 1998 increased by 14% compared to
fiscal 1997 due to the increase in operating revenue. As a percentage of
operating revenue, the gross profit in fiscal 1998 was 4.93% as compared to
4.94% in the prior fiscal year. The small decline in gross profit percentage
was due to a reduction in selling margin percentage due to strong competition
in the industry as well as continued customer consolidation offset in part by
an increase in inventory appreciation profits.
In the third quarter of fiscal 1997, the Company commenced cost reduction
plans to consolidate three of its pharmaceutical distribution facilities into
other existing facilities and to restructure its sales force. These cost
reduction initiatives resulted in a $6.4 million charge in the third fiscal
quarter of 1997. In addition, the Company incurred charges of $5.2 million
related to the retirement of its former President and CEO as well as other
executive terminations. The $6.4 million charge included $1.8 million for the
severance of approximately 240
12
<PAGE>
warehouse and sales personnel and $4.6 million of asset write-downs and lease
cancellation costs primarily for buildings, warehouse and computer equipment
and other assets to be disposed of related to the facility consolidations. The
fiscal 1997 cost reduction initiatives were completed early in fiscal 1998.
Selling and administrative expenses and depreciation increased by $28.1
million or 11% in fiscal 1998 compared with the prior fiscal year, and as a
percentage of operating revenue, were 3.14% in fiscal 1998 and 3.26% in fiscal
1997. The increase in selling and administrative expenses and depreciation for
the year is primarily due to the impact of a full year of expenses from the
October 1997 acquisition of General Drug and the March 1997 acquisition of
Walker Drug Company. The decrease in the expense to operating revenue ratio
for the year was primarily due to benefits resulting from the fiscal 1997 cost
reduction initiatives discussed above as well as the shift in customer mix
resulting from the termination of service contracts with the two large
warehousing chain customers.
Operating income of $138.9 million for the year ended September 30, 1998
increased by 11% from the prior year. The Company's operating margin decreased
to 1.48% in fiscal 1998 from 1.53% in fiscal 1997. This decrease in operating
margin was due primarily to the $18.4 million of merger costs described above.
In addition, both years have been impacted by the charges related to facility
consolidations and employee severance discussed above.
Interest expense of $50.4 million in fiscal 1998 represents an increase of
16% compared to the prior year as average borrowings for the year increased by
16%. Average borrowings during the year ended September 30, 1998 were $714
million compared to average borrowings of $618 million in the prior fiscal
year. Approximately 60% of this increase was due to C.D. Smith's acquisition
of General Drug. Interest rate step-downs of 50 basis points during fiscal
1998 were achieved under the Company's revolving credit facility as a result
of attaining certain financial ratios. The reduced borrowing rates under the
$500 million credit facility were offset by the higher rates on C.D. Smith
long term-debt as a result of its acquisition of General Drug in October,
1997. Market interest rates were relatively flat during fiscal 1998.
Interest expense-adjustment of common stock put warrant to fair value of
$7.8 million represents the adjustment to fair value of $10.4 million at
September 30, 1998 of the common stock put warrant issued to the holders of
the subordinated note used to help finance C.D. Smith's acquisition of General
Drug in October 1997.
Income tax expense of $34.7 million in fiscal 1998 reflected an effective
tax rate of 43.0% versus 39.0% in the prior year. The increase in the rate was
due to the non-deductible interest expense-adjustment of common stock put
warrant to fair value in fiscal 1998.
Income before extraordinary items decreased to $46.0 million in fiscal 1998
from $50.1 million in fiscal 1997. Income before extraordinary items per
share-assuming dilution was $.91 in fiscal 1998, a 9% decrease from fiscal
1997. The effect of the merger costs and charges related to facility closings
and employee severance are included in these amounts. In addition the non-cash
interest expense-adjustment of common stock put warrant to fair value
contributed to the decline from the prior year.
Liquidity and Capital Resources
During the year ended September 30, 1999, the Company's operating activities
generated $3.0 million in cash as compared to $120.9 million generated in the
prior year. Cash generation from operations in the current year was impacted
by an increase in accounts receivable of $111.7 million primarily due to the
15% growth in operating revenue in the fourth quarter of fiscal 1999 as
compared to the similar period in the prior year as well as the $289.1 million
increase in merchandise inventories which was offset in part by the $246.3
increase in accounts payable, accrued expenses and income taxes. Merchandise
inventories increased to support new customer contracts, provide for seasonal
buying opportunities and provide for year 2000 supply concerns. This trend is
expected to continue through the first quarter of fiscal 2000. A decrease in
restricted cash of $41.8 million in fiscal 1999 due to the extinguishment of
the Company's prior receivables securitization facility also offset the
increase in receivables and inventories.
13
<PAGE>
During the year ended September 30, 1998, the Company's operating activities
generated $120.9 million in cash primarily due to a decrease in accounts
receivable of $72.0 million. The reduction in accounts receivable was due to a
combination of improved collection efforts and the loss of the three major
customers described above. As a result of the reduction in accounts
receivable, the collateral base for the Company's prior receivables
securitization facility at September 30, 1998 was less than the $299.9 million
of fixed certificates then outstanding, resulting in an increase in restricted
cash to supplement the collateral base. The provision for deferred income
taxes increased operating cash flow by $19.5 million primarily due to an
increase in deferred tax liabilities related to inventory. A decrease in
merchandise inventory in fiscal 1998 of $133.6 million was offset by a related
decrease of $168.0 million in accounts payable, accrued expenses, and income
taxes. These decreases were also impacted by the termination of service
contracts with the three large customers in fiscal 1998 as well as the
reversal of the fiscal 1997 year-end build of inventory related to the
Company's expansion of its Thorofare, New Jersey distribution facility. The
Company paid a total of $5.2 million and $6.1 million of severance and
contract and lease cancellation costs and other in fiscal 1999 and 1998,
respectively, related to its fiscal 1999, 1998 and 1997 cost reduction plans
discussed above. Severance accruals of $2.9 million and remaining contract and
lease obligations of $4.3 million at September 30, 1999 are included in
accrued expenses and other.
Capital expenditures for the years ended September 30, 1999 and 1998 were
$15.8 and $12.1 million, respectively, and relate principally to investments
in warehouse improvements, information technology and warehouse automation.
Similar expenditures of approximately $18 to $20 million are expected in
fiscal 2000.
In fiscal 1998, C.D. Smith acquired the equity interests of the General Drug
companies for $28 million which was financed through borrowings under its
credit facility of $16.0 million and the issuance of a subordinated note for
$12.0 million. In addition, C.D. Smith refinanced approximately $39.5 million
of indebtedness of the General Drug companies.
Cash provided by financing activities during fiscal 1999 represents
borrowings under the Company's revolving credit and receivable securitization
facilities primarily to fund its working capital requirements. In connection
with its acquisition of C.D. Smith in fiscal 1999, the Company extinguished
approximately $78 million of C.D. Smith's long-term debt through borrowings
under its revolving credit facility. In fiscal 1998, cash used by financing
activities represented net repayments of the Company's revolving credit
facility from cash provided by operations, and in fiscal 1997 cash provided by
financing activities was primarily used to fund the acquisition of Walker Drug
Company in March 1997.
At September 30, 1999, borrowings under the Company's $500 million revolving
credit facility were $225.2 million and borrowings under its $325 million
receivables securitization facility were $325.0 million. The revolving credit
facility expires in January 2002 and provides for interest rates ranging from
LIBOR plus 25 basis points to LIBOR plus 125 basis points based upon certain
financial ratios. In May 1999, the Company entered into a new $325 million
receivables securitization facility to replace its previous facility. The new
facility has a term of three years and interest is at a rate at which funds
are obtained by the financial institution to fund the receivable (short-term
commercial paper rates) plus a program fee of 38.5 basis points. The
receivables securitization facility represents a financing vehicle utilized by
the Company because of the availability of attractive interest rates relative
to other financing sources. The Company securitizes its trade accounts and
note receivables, which are generally non-interest bearing, in transactions
that do not qualify as sales transactions under SFAS No. 125. In October 1999,
the Company entered into a short-term supplemental $200 million senior secured
revolving credit agreement with interest at a rate equal to LIBOR plus 137.5
basis points. This agreement expires March 31, 2000 and is intended to fund
seasonal inventory purchases if necessary.
The Company's primary exposure to market risk consists of changes in
interest rates on borrowings. An increase in interest rates would adversely
affect the Company's operating results and the cash flow available after debt
service to fund operations and expansion and, if permitted to do so under its
revolving credit facility, to pay dividends on its capital stock. The Company
enters into interest rate protection agreements from time to time to hedge the
exposure to increasing interest rates with respect to its long-term debt
agreements. The Company provides protection to meet actual exposure and does
not speculate in derivatives. For every $100 million of
14
<PAGE>
unhedged variable rate debt, a 75 basis point increase in interest rates would
increase the Company's annual interest expense by $0.75 million.
The Company's operating results have generated sufficient cash flow which,
together with borrowings under its debt agreements and credit terms from
suppliers, have provided sufficient capital resources to finance working
capital and cash operating requirements, fund capital expenditures, and
interest currently payable on outstanding debt. The Company's primary ongoing
cash requirements will be to finance working capital, fund payment of interest
on indebtedness, and fund capital expenditures and routine growth and
expansion through new business opportunities. Future cash flows from
operations and borrowings are expected to be sufficient to fund the Company's
ongoing cash requirements.
In 1998 the Company sued a former customer which refused to pay invoices,
net of credit memos, totaling approximately $21 million for goods sold and
delivered. The former customer has filed counterclaims alleging it suffered
damages as a result of certain performance problems affecting the Company. The
Company believes there is no merit to these counterclaims and is aggressively
pursuing collection of the outstanding amount. A trial is scheduled for
January 2000 and ultimate collectibility of amounts owed to the Company is
dependent on the outcome of the trial and the continued creditworthiness of
the former customer.
The Company is subject to certain contingencies pursuant to environmental
laws and regulations at one of its former distribution centers that may
require remediation efforts. In fiscal 1994, the Company accrued a liability
of $4.1 million to cover future consulting, legal and remediation, and ongoing
monitoring costs. The accrued liability ($3.8 million at September 30, 1999),
which is reflected in other long-term liabilities on the accompanying
consolidated balance sheet, is based on an estimate of the extent of
contamination and choice of remedy, existing technology, and presently enacted
laws and regulations, however, changes in remediation standards, improvements
in cleanup technology, and discovery of additional information concerning the
site could affect the estimated liability in the future.
Year 2000 Issue
General Description of the Year 2000 Issue and the Nature and Effects of the
Year 2000 on Information Technology (IT) and Non-IT Systems
The Year 2000 Issue is the result of computer programs being written using
two digits rather than four to define the applicable year. Any of the
Company's computer programs that have date-sensitive software or embedded
chips may recognize a date using "00" as the year 1900 rather than the year
2000. This could result in a system failure or miscalculations causing
disruptions of operations, including, among other things, a temporary
inability to process transactions, send invoices, or engage in similar normal
business practices.
The Company began addressing the Year 2000 Issue in 1995 on a decentralized
basis at each of its regional data processing centers. In 1997, the Company
began monitoring progress on a corporate level and a formal Year 2000
committee, reporting to senior management, was established in early 1998 to
coordinate and monitor the Year 2000 Issue on an enterprise-wide basis. Based
on assessments made since 1995, the Company determined that modifications to
or in limited cases replacement of computer software and hardware was
necessary to enable those systems to operate properly after December 31, 1999.
The Company's plan to resolve the Year 2000 Issue involved the following
four phases: assessment, remediation, testing, and implementation. To date,
the Company has completed its assessment of all systems that could be
significantly affected by the Year 2000. The assessment indicated that most of
the Company's significant information technology systems could be affected,
particularly the Company's warehouse and distribution operating and accounting
systems. The assessment also indicated that software and hardware (embedded
chips) used in warehouse automation, scanning, and ordering as well as other
equipment used in the distribution process (operating equipment) are also at
risk. Because the Company is a distributor of pharmaceuticals, the Company's
products are not at risk.
Status of Progress in Becoming Year 2000 Compliant
For its information technology exposures, the Company has completed the
remediation phase, including software reprogramming and replacement. Once
software is reprogrammed or replaced for a system, the
15
<PAGE>
Company begins testing and implementation. These phases run concurrently for
different systems. The Company has completed its testing and has implemented
all remediated systems.
The remediation of operating equipment with embedded chips or software has
also been completed. Testing of the affected equipment and implementation of
affected equipment is also complete.
Nature and Level of Importance of Third Parties and their Exposure to the
Year 2000
Many of the Company's customers order products from the Company using
ECHO(R), the Company's proprietary software system. ECHO(R) was developed in-
house and has been Year 2000 compliant from its inception. The Company also
issues the majority of its purchase orders to vendors through the use of
Electronic Data Interchange ("EDI"). The Company is complete with its
remediation, testing and implementation efforts relating to EDI software.
In February 1999, the Company sent surveys to over 6,000 customers to assess
their Year 2000 compliance. The Company surveyed its top 100 vendors in May,
1999 and has also visited the majority of its top 50 vendors to assess Year
2000 compliance plans. Based on the nature of their responses, the Company has
developed contingency plans as appropriate. However, the Company has no means
of assuring that external customers and vendors will be Year 2000 compliant.
The inability of these third parties to complete their Year 2000 resolution
process in a timely fashion could materially impact the Company.
Costs
The Company has utilized both internal and external resources to reprogram,
or replace, test, and implement the software and operating equipment for Year
2000 modifications. Many of the program fixes were completed in conjunction
with other projects and had little incremental cost. The Company spent less
than $1 million on Year 2000 projects in fiscal 1999.
Risks
Management of the Company believes that it has an effective program in place
to resolve the Year 2000 Issue. Because of the range of possible issues and
the large number of variables involved, it is impossible to quantify the
potential cost of problems should the Company or its trading partners not
properly execute their Year 2000 plans. Such costs and any failure of
compliance efforts could have a material adverse effect on the Company. The
Company believes that the most likely risks of serious Year 2000 business
disruption are external in nature, including continuity of utility,
telecommunication and transportation services, and the potential failure of
the Company's customers due to their own non-compliance or the non-compliance
of their business partners. In addition, the Company may be affected by
disruptions in the supply channel due to excess demand for inventory by
customers in anticipation of Year 2000 problems as well as potential changes
in supplier pricing practices which may impact the Company's gross profit. In
the event the Company has not properly completed its Year 2000 efforts or is
affected by the disruption of outside services, the Company could be unable to
take orders, distribute goods, invoice customers or collect payments. In
addition, disruptions in the economy generally resulting from Year 2000 could
have a material adverse effect on the Company. The Company could be subject to
litigation for computer systems failure. The amount of potential liability and
lost revenue cannot be reasonably estimated at this time.
Contingency Plans
The Company has completed contingency plans to address the above Year 2000
risks. Contingency plans have been completed for all of its drug distribution
facilities and for its centralized data processing system. In addition, as
previously mentioned, the Company entered into a supplemental credit facility
of up to $200 million to protect itself against any potential year 2000
disruptions. In the normal course of business, the Company has contingency
plans for disruption of business events and has augmented those plans with
specific Year 2000 considerations.
16
<PAGE>
Forward Looking Statements
Certain information in this Management's Discussion and Analysis of
Financial Condition and Results of Operations contains forward-looking
statements as such term is defined in Section 27A of the Securities Act and
Section 21E of the Exchange Act. Certain factors such as changes in interest
rates, market technology, competitive pressures, customer and product mix,
supplier pricing practices, inventory investment buying opportunities,
regulatory changes, the Year 2000 Issue and capital markets could cause actual
results to differ materially from those in forward-looking statements.
Item 7a. Quantitative and Qualitative Disclosures About Market Risk
See discussion in Item 7.
17
<PAGE>
Item 8. Financial Statements and Supplementary Data
REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
To the Board of Directors and Stockholders of
AmeriSource Health Corporation
We have audited the accompanying consolidated balance sheets of AmeriSource
Health Corporation and subsidiaries as of September 30, 1999 and 1998, and the
related consolidated statements of operations, changes in stockholders'
equity, and cash flows for each of the three years in the period ended
September 30, 1999. Our audits also included the financial statement schedules
listed in the Index at Item 14(a). These financial statements and schedules
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these financial statements and schedules based on our
audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the consolidated financial position
of AmeriSource Health Corporation and subsidiaries at September 30, 1999 and
1998 and the consolidated results of their operations and their cash flows for
each of the three years in the period ended September 30, 1999, in conformity
with generally accepted accounting principles. Also, in our opinion, the
related financial statement schedules, when considered in relation to the
basic financial statements taken as a whole, present fairly in all material
respects the information set forth therein.
Ernst & Young LLP
Philadelphia, Pennsylvania
November 3, 1999
18
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
ASSETS
<TABLE>
<CAPTION>
September 30,
---------------------
1999 1998
---------- ----------
<S> <C> <C>
Current assets:
Cash and cash equivalents ............................. $ 59,497 $ 48,511
Restricted cash........................................ -- 41,833
Accounts receivable, less allowance for doubtful
accounts: 1999--$27,583
1998--$27,498......................................... 612,520 509,130
Merchandise inventories................................ 1,243,153 954,010
Prepaid expenses and other............................. 4,836 5,042
---------- ----------
Total current assets................................. 1,920,006 1,558,526
Property and equipment, at cost:
Land................................................... 4,125 4,180
Buildings and improvements............................. 38,855 37,155
Machinery, equipment and other......................... 91,760 86,395
---------- ----------
134,740 127,730
Less accumulated depreciation.......................... 70,356 59,775
---------- ----------
64,384 67,955
Other assets, less accumulated amortization: 1999--
$8,967, 1998--$10,157................................... 76,209 99,791
---------- ----------
$2,060,599 $1,726,272
========== ==========
</TABLE>
19
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except per share data)
LIABILITIES AND STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
September 30,
----------------------
1999 1998
---------- ----------
<S> <C> <C>
Current liabilities:
Accounts payable..................................... $1,175,619 $ 947,016
Accrued expenses and other........................... 50,329 52,188
Accrued income taxes................................. 10,854 466
Deferred income taxes................................ 90,481 93,362
---------- ----------
Total current liabilities.......................... 1,327,283 1,093,032
Long-term debt:
Revolving credit facilities.......................... 225,227 218,590
Receivables securitization financing................. 325,000 299,948
Other debt........................................... 8,478 20,926
---------- ----------
558,705 539,464
Other liabilities...................................... 8,334 8,036
Common stock put warrant............................... -- 10,385
Stockholders' equity:
Common stock, $.01 par value:
Class A (voting and convertible):
100,000,000 shares authorized; issued 9/99--
51,737,893 shares;
9/98--46,582,950 shares........................... 517 466
Class B (nonvoting and convertible):
15,000,000 shares authorized; issued 9/99--
5,908,445 shares;
9/98--11,401,566 shares........................... 59 114
Class C (nonvoting and convertible):
2,000,000 shares authorized; issued 9/99--165,936
shares;
9/98--258,474 shares.............................. 2 2
Capital in excess of par value....................... 266,737 244,556
Accumulated deficit.................................. (94,632) (162,098)
Cost of common stock in treasury..................... (6,220) (7,353)
Note receivable from ESOP............................ (186) (332)
---------- ----------
166,277 75,355
---------- ----------
$2,060,599 $1,726,272
========== ==========
</TABLE>
See notes to consolidated financial statements.
20
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
<TABLE>
<CAPTION>
Fiscal year ended September 30,
---------------------------------
1999 1998 1997
---------- ---------- ----------
<S> <C> <C> <C>
Operating revenue........................... $9,760,083 $9,373,482 $8,173,679
Bulk deliveries to customer warehouses...... 47,280 129,555 124,956
---------- ---------- ----------
Total revenue............................... 9,807,363 9,503,037 8,298,635
Operating cost of goods sold................ 9,287,018 8,911,585 7,769,543
Cost of goods sold--bulk deliveries......... 47,280 129,555 124,956
---------- ---------- ----------
Total cost of goods sold.................... 9,334,298 9,041,140 7,894,499
---------- ---------- ----------
Gross profit................................ 473,065 461,897 404,136
Selling and administrative.................. 281,798 279,392 254,354
Depreciation................................ 15,387 14,810 11,707
Amortization................................ 1,986 2,075 1,059
Merger costs................................ 3,162 18,406 --
Facility consolidations and employee
severance.................................. 11,730 8,283 11,571
---------- ---------- ----------
Operating income............................ 159,002 138,931 125,445
Interest expense............................ 39,356 50,363 43,259
Interest expense-adjustment of common stock
put warrants to fair value................. 334 7,816 --
---------- ---------- ----------
Income before taxes and extraordinary items. 119,312 80,752 82,186
Taxes on income............................. 48,397 34,722 32,063
---------- ---------- ----------
Income before extraordinary items........... 70,915 46,030 50,123
Extraordinary items--early retirement of
debt, net of income tax benefits........... 3,449 -- 1,982
---------- ---------- ----------
Net income.................................. $ 67,466 $ 46,030 $ 48,141
========== ========== ==========
Earnings per share:
Income before extraordinary items......... $ 1.40 $ .92 $ 1.01
Extraordinary items....................... (.07) -- (.04)
---------- ---------- ----------
Net income.............................. $ 1.33 $ .92 $ .97
========== ========== ==========
Earnings per share--assuming dilution:
Income before extraordinary items......... $ 1.38 $ .91 $ 1.00
Extraordinary items....................... (.07) -- (.04)
---------- ---------- ----------
Net income.............................. $ 1.31 $ .91 $ .96
========== ========== ==========
Weighted average common shares outstanding:
Basic..................................... 50,698 49,877 49,467
Assuming dilution......................... 51,683 50,713 50,301
</TABLE>
See notes to consolidated financial statements.
21
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES
IN STOCKHOLDERS' EQUITY
(in thousands)
<TABLE>
<CAPTION>
Cost of
Common Stock Capital in Common
----------------------- Excess of Accumulated Stock in ESOP Note
Class A Class B Class C Par Value Deficit Treasury Receivable Total
------- ------- ------- ---------- ----------- -------- ---------- ---------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
September 30, 1996...... $380 $188 $ 6 $ 228,433 $(256,269) $ (6,972) $(622) $ (34,856)
Net income............. 48,141 48,141
Stock conversions...... 2 (2) --
Exercise of stock
options............... 2 3,807 3,809
Tax benefit from
exercise of stock
options............... 1,843 1,843
Collections on ESOP
note.................. 145 145
Purchases of treasury
stock................. (201) (201)
---- ---- ---- --------- --------- -------- ----- ---------
September 30, 1997...... 384 188 4 234,083 (208,128) (7,173) (477) 18,881
Net income............. 46,030 46,030
Stock conversions ..... 76 (74) (2) --
Exercise of stock
options............... 6 6,676 6,682
Tax benefit from
exercise of stock
options............... 3,797 3,797
Collections on ESOP
note.................. 145 145
Purchases of treasury
stock................. (180) (180)
---- ---- ---- --------- --------- -------- ----- ---------
September 30, 1998...... 466 114 2 244,556 (162,098) (7,353) (332) 75,355
---- ---- ---- --------- --------- -------- ----- ---------
Net income............. 67,466 67,466
Stock conversions...... 55 (55) --
Exercise of stock
options............... 5 8,901 75 8,981
Tax benefit from
exercise of stock
options............... 4,058 4,058
Collections on ESOP
note.................. 146 146
Purchases of treasury
stock................. (449) (449)
Exercise of common
stock put warrant .... 10,262 458 10,720
Retirement of treasury
stock................. (9) (1,040) 1,049 --
---- ---- ---- --------- --------- -------- ----- ---------
September 30, 1999...... $517 $ 59 $ 2 $ 266,737 $(94,632) $(6,220) $(186) $166,277
==== ==== ==== ========= ========= ======== ===== =========
</TABLE>
See notes to consolidated financial statements.
22
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
<TABLE>
<CAPTION>
Fiscal year ended September 30,
------------------------------------
1999 1998 1997
---------- ----------- -----------
<S> <C> <C> <C>
OPERATING ACTIVITIES
Net income.............................. $ 67,466 $ 46,030 $ 48,141
Adjustments to reconcile net income to
net cash provided by (used in)
operating activities:
Depreciation........................... 15,387 14,810 11,707
Amortization, including deferred
financing costs....................... 4,457 4,716 2,938
Adjustment of common stock put warrant
to fair value......................... 334 7,816 --
Provision for loss on accounts
receivable............................ 6,956 9,990 6,705
Loss (gain) on disposal of property and
equipment............................. 320 (197) (181)
Provision for deferred income taxes.... 11,283 19,451 (5,102)
Loss on early retirement of debt....... 3,557 -- 3,250
Write-downs of assets.................. 6,400 2,168 3,857
Changes in operating assets and
liabilities, excluding the effects of
acquisitions:
Restricted cash........................ 41,833 (26,323) (3,293)
Accounts and notes receivable.......... (111,744) 72,001 (78,261)
Merchandise inventories................ (289,143) 133,571 (273,700)
Prepaid expenses and other............. (1,049) 5,244 (924)
Accounts payable, accrued expenses, and
income taxes.......................... 246,289 (168,000) 274,794
Miscellaneous.......................... 654 (361) (552)
---------- ----------- -----------
NET CASH PROVIDED BY (USED IN) OPERATING
ACTIVITIES.............................. 3,000 120,916 (10,621)
INVESTING ACTIVITIES
Capital expenditures.................... (15,793) (12,101) (16,302)
Cost of companies acquired.............. -- (29,097) (130,962)
Purchase of equity interest in a
business............................... (3,570) -- --
Collections on ESOP note receivable..... 146 145 145
Proceeds from sales of property and
equipment.............................. 2,436 2,455 1,934
Other................................... -- -- 53
---------- ----------- -----------
NET CASH USED IN INVESTING ACTIVITIES.... (16,781) (38,598) (145,132)
FINANCING ACTIVITIES
Long-term debt borrowings............... 2,373,656 2,433,210 2,462,463
Long-term debt repayments............... (2,356,807) (2,531,954) (2,312,063)
Deferred financing costs and other ..... (614) (1,645) (3,775)
Purchases of treasury stock............. (449) (180) (201)
Exercise of stock options and warrant... 8,981 6,682 3,809
---------- ----------- -----------
NET CASH PROVIDED BY (USED IN) FINANCING
ACTIVITIES.............................. 24,767 (93,887) 150,233
---------- ----------- -----------
INCREASE (DECREASE) IN CASH AND CASH
EQUIVALENTS............................. 10,986 (11,569) (5,520)
Cash and cash equivalents at beginning of
year.................................... 48,511 60,080 65,600
---------- ----------- -----------
CASH AND CASH EQUIVALENTS AT END OF YEAR. $ 59,497 $ 48,511 $ 60,080
========== =========== ===========
</TABLE>
See notes to consolidated financial statements.
23
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 1999
Note 1--Summary of Significant Accounting Policies
Basis of Presentation
The accompanying consolidated financial statements include the accounts of
AmeriSource Health Corporation and its wholly-owned subsidiaries (the
"Company") as of the dates and for the fiscal years indicated. All
intercompany transactions and balances have been eliminated in consolidation.
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect amounts reported in the financial statements and
accompanying notes. Actual amounts may differ from these estimated amounts.
Business
The Company is a wholesale distributor of pharmaceuticals and related health
care products within the United States.
Business Combinations
Business combinations accounted for under the purchase method of accounting
include the results of operations of the acquired business from the date of
acquisition. Net assets of the companies acquired are recorded at their fair
value to the Company at the date of acquisition (see Note 2).
For business combinations accounted for under the pooling-of-interests
method of accounting, the assets, liabilities and stockholders' equity of the
acquired entities were combined with the Company's respective accounts at
recorded values. Prior period financial statements have been restated to give
effect to the combination (see Note 2).
Cash Equivalents
The Company classifies highly liquid investments with original maturities of
three months or less at date of purchase as cash equivalents.
Concentrations of Credit Risk
The Company sells its merchandise inventories to a large number of customers
in the health care industry, including independent drug stores, chain drug
stores, hospitals, mass merchandisers, clinics, and nursing homes. The
Company's trade accounts receivable are exposed to credit risk, but the risk
is limited due to the diversity of the customer base and the customer base's
wide geographic dispersion. The Company performs ongoing credit evaluations of
its customers' financial condition. The Company maintains reserves for
potential bad debt losses and such bad debt losses have been within the
Company's expectations.
The Company maintains cash balances at several large creditworthy banks
located in the United States. Accounts at each institution are insured by the
Federal Deposit Insurance Corporation up to $100,000. The Company does not
believe there is significant credit risk related to its cash balances.
Merchandise Inventories
Inventories are stated at the lower of cost or market. Cost is determined
using the last-in, first-out (LIFO) method, which results in a matching of
current costs and revenues. If the first-in, first-out (FIFO) method of
valuation had been used for determining costs, inventories would have been
approximately $98.9 million and $96.1 million higher than the amounts reported
at September 30, 1999 and 1998, respectively.
24
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 1--Summary of Significant Accounting Policies--(continued)
Property and Equipment
Property and equipment are stated at cost and depreciated on the straight-
line method over the estimated useful lives of the assets which range from
three to 40 years.
Revenue Recognition
The Company recognizes revenues when products are delivered to customers.
The Company also acts as an intermediary in the bulk shipment of
pharmaceuticals from manufacturers to customers' warehouses. These bulk
deliveries are included in total revenue.
Stock-Based Compensation
The Company follows Accounting Principles Board ("APB") Opinion No. 25,
"Accounting for Stock Issued to Employees," and related interpretations in
accounting for its employee stock-based compensation (See Note 8).
Employee Stock Ownership Plan
The Company follows Statement of Position (SOP) 76-3, "Accounting Practices
for Certain Employee Stock Ownership Plans," issued by the American Institute
of Certified Public Accountants (AICPA). The amount contributed or committed
to be contributed to the C.D. Smith Healthcare, Inc. Employee Stock Ownership
Plan (ESOP) with respect to a given year is charged to expense. The
compensation and interest elements of the contribution are separately reported
(See Note 7).
Earnings Per Share and Share Data
Earnings per share is computed on the basis of the weighted average number
of shares of common stock outstanding during the periods presented. Earnings
per share--assuming dilution is computed on the basis of the weighted average
numbers of shares outstanding during the period plus the dilutive effect of
stock options and warrants. All shares held by the ESOP are considered
outstanding for purposes of computing earnings per share.
The Company's earnings per share and share data in the financial statements
have been restated to reflect the effect of a two-for-one stock split in March
1999.
Recently Issued Financial Accounting Standards
In fiscal 1998, the FASB issued SFAS No. 133 "Accounting for Derivative
Instruments and Hedging Activities," which requires companies to recognize all
derivatives as either assets or liabilities in the balance sheet and measure
such instruments at fair value. SFAS No. 133 is effective for fiscal years
beginning after June 15, 2001. Adoption of these statements will not impact
the Company's consolidated financial position, results of operations or cash
flows, and any effect will be limited to the form and content of its
disclosures.
Note 2--Acquisitions
On July 8, 1999, the Company acquired C.D. Smith Healthcare, Inc. ("C.D.
Smith"). Based in St. Joseph, Missouri, C.D. Smith was the seventh largest
wholesale pharmaceutical distributor with annual operating revenue of
approximately $800 million. Shareholders of C.D. Smith received a fixed
exchange of approximately 2.44 million shares of the Company's common stock
and .25 million common stock options for all of the outstanding common stock
and common stock options of C.D. Smith. The Company assumed $78 million in
long-term debt for a total transaction value of approximately $147 million
based on the Company's closing stock price on July 8, 1999. The assumed long-
term debt was immediately extinguished with funds provided by the Company's
revolving credit facility, resulting in an extraordinary charge in the fourth
quarter of fiscal 1999 of $2.8 million net of taxes of $1.6 million, relating
to prepayment penalties and the write-off of unamortized original issue
25
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 2--Acquisitions--(continued)
discount and deferred financing fees. The business combination was accounted
for under the pooling-of-interests method of accounting and, accordingly, the
accompanying financial statements and footnotes have been restated to include
the operations of C.D. Smith for all periods presented. For the fiscal years
ended September 30, 1999 (through the date of the acquisition), 1998 and 1997,
C.D. Smith's revenues were approximately $621.5 million, $834.2 million, and
$357.7 million, respectively. For the fiscal years ended September 30, 1999
(through the date of the acquisition), 1998 and 1997, C.D. Smith's net income
(loss) was approximately $1.6 million, $(4.5) million and $2.7 million,
respectively.
On October 3, 1997, C.D. Smith acquired all of the outstanding partnership
interests in Gimbel, which owned 100% of the outstanding stock of Holdings,
the parent company of the General Drug Companies ("General Drug"), for $28.0
million in cash. General Drug is a wholesale pharmaceutical distributor based
in Chicago, Illinois and Boston, Massachusetts, which had annual revenues of
approximately $370 million. The transaction was accounted for using the
purchase method. The excess of the purchase price, over the fair market value
of the net assets acquired amounted to $25.8 million, of which $12.0 million
was allocated to customer lists and $13.8 million was allocated to goodwill.
Goodwill is being amortized over 40 years and customer lists are being
amortized over 20 years on a straight-line basis. Both goodwill and customer
lists are included in other assets.
During fiscal 1997, the Company acquired all of the equity interests of
Walker Drug Company, L.L.C. in a cash transaction. Walker Drug Company, L.L.C.
is a wholesale pharmaceutical distributor based in Pelham, Alabama, which had
annual revenues of approximately $800 million. The aggregate purchase price,
including the assumption of long-term debt, was approximately $138.7 million
and was financed by borrowings under the Company's revolving credit facility.
This acquisition was accounted for by the purchase method. The excess of
purchase price over net assets acquired of $27.4 million has been allocated to
goodwill and is being amortized on a straight-line basis over 40 years.
The following unaudited table (in thousands, except per share data) reflects
financial results on a pro forma basis, assuming the fiscal 1998 and 1997
acquisitions had occurred at the beginning of the period presented. Pro forma
adjustments include: increased amortization for the cost over net assets
acquired; increased interest expense associated with financing the
acquisitions; and related income tax effects. Cost savings from combining the
operations are not reflected.
<TABLE>
<CAPTION>
Fiscal year ended
September 30, 1997
------------------
<S> <C>
Total revenue................................................ $9,070,611
Income before extraordinary items............................ 48,700
Net income................................................... 46,718
Earnings per share--assuming dilution:
Income before extraordinary item........................... $ .97
Extraordinary item......................................... (.04)
----------
Net income............................................... $ .93
==========
</TABLE>
The unaudited pro forma information is provided for information purposes
only and does not purport to be indicative of the Company's results of
operations that would actually have been achieved had the acquisitions been
completed for the periods presented, or results that may be obtained in the
future.
26
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 3--Taxes on Income
The income tax provision (benefit) is as follows (in thousands):
<TABLE>
<CAPTION>
Fiscal year ended
September 30,
-----------------------
1999 1998 1997
------- ------- -------
<S> <C> <C> <C>
Current provision:
Federal........................................ $34,108 $14,253 $31,192
State and local................................ 3,006 1,018 5,973
------- ------- -------
37,114 15,271 37,165
Deferred provision:
Federal........................................ 8,106 15,538 (4,163)
State and local................................ 3,177 3,913 (939)
------- ------- -------
11,283 19,451 (5,102)
------- ------- -------
Provision for income taxes....................... $48,397 $34,722 $32,063
======= ======= =======
</TABLE>
A reconciliation of the statutory federal income tax rate to the effective
income tax rate is as follows:
<TABLE>
<CAPTION>
Fiscal year ended September 30,
------------------------------------
1999 1998 1997
---------- ---------- ----------
<S> <C> <C> <C>
Statutory federal income tax rate. 35.0% 35.0% 35.0%
State and local income tax rate,
net of federal tax benefit....... 3.4 4.0 4.0
Tax effect of goodwill write-down. 1.7 -- --
Tax effect of warrant accretion... .1 3.3 --
Other............................. .4 .7 --
---------- ---------- ----------
Effective income tax rate......... 40.6% 43.0% 39.0%
========== ========== ==========
</TABLE>
Deferred income taxes reflect the future tax consequences of differences
between the tax bases of assets and liabilities and their financial reporting
amounts. Significant components of the Company's deferred tax liabilities
(assets) are as follows (in thousands):
<TABLE>
<CAPTION>
September 30,
--------------------
1999 1998
--------- ---------
<S> <C> <C>
Inventory........................................... $ 117,251 $ 126,986
Fixed assets........................................ 5,674 5,500
Other............................................... 945 1,092
--------- ---------
Gross deferred tax liabilities.................. 123,870 133,578
Net operating losses and tax credit carryovers...... (22,239) (48,316)
Allowance for doubtful accounts..................... (10,290) (9,626)
Accrued expenses.................................... (1,694) (2,107)
Other postretirement benefits....................... (541) (537)
Other............................................... (9,595) (9,619)
--------- ---------
Gross deferred tax assets....................... (44,359) (70,205)
Valuation allowance for deferred tax assets......... 1,122 2,222
--------- ---------
Net deferred tax liabilities........................ $ 80,633 $ 65,595
========= =========
</TABLE>
27
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 3--Taxes on Income--(continued)
In fiscal 1999, 1998, and 1997 tax benefits of $4.1 million, $3.8 million
and $1.8 million, respectively, related to the exercise of employee stock
options were recorded as capital in excess of par value.
As of September 30, 1999, the Company has $1.4 million of potential tax
benefits from state net operating losses expiring in 4 to 14 years. As of
September 30, 1999, the Company had $20.8 million of alternative minimum tax
credit carryforwards.
Income tax payments amounted to $17.0 million, $17.4 million, and $20.2
million in the fiscal years ended September 30, 1999, 1998, and 1997,
respectively.
Note 4--Long-Term Debt
Receivables Securitization Financing
Effective May 14, 1999, the Company, through a consolidated wholly-owned
special purpose entity, established a new receivables securitization facility
(the "1999 Securitization Facility"), which provides the Company with up to
$325 million in available credit. In connection with the 1999 Securitization
Facility, the Company will sell on a revolving basis certain accounts
receivables to the special purpose entity which in turn sells a percentage
ownership interest in the receivables to a commercial paper conduit sponsored
by a financial institution. The Company was retained as servicer of the sold
accounts receivables. The 1999 Securitization Facility has a term of three
years. Interest is at a rate at which funds are obtained by the financial
institution to fund the receivables (short-term commercial paper rates) plus a
program fee of 38.5 basis points (5.74% at September 30, 1999). The Company is
required to pay a commitment fee of 25 basis points on any unused credit in
excess of $25 million under the facility. Fees of $0.6 million incurred to
establish the 1999 Securitization Facility were deferred and will be amortized
on a straight-line basis over the term of the 1999 Securitization Facility.
The transaction does not qualify as a "sale" in accordance with SFAS No. 125,
"Accounting for Transfers and Servicing of Financial Assets and Extinguishment
of Liabilities," and, accordingly, the Company accounts for the 1999
Securitization Facility as a financing transaction in its consolidated
financial statements.
Proceeds from the 1999 Securitization Facility were used to extinguish the
Company's prior receivables securitization financing ("Receivables Program")
in the fourth quarter of fiscal 1999 and resulted in an extraordinary charge
of $0.7 million (net of a $0.4 million tax benefit) related to the write-off
of unamortized deferred financing fees.
Under the Receivables Program, the Company sold substantially all of its
trade accounts and notes receivable (the "Receivables") to AmeriSource
Receivables Corporation ("ARC"), a special-purpose, wholly-owned subsidiary,
through a Receivables Purchase Agreement with ARC, whereby ARC purchased on a
continuous basis Receivables originated by the Company. Pursuant to the
Receivables Program, ARC transferred such Receivables to a master trust in
exchange for, among other things, certain trade receivables-backed
certificates (the "Certificates"). During the term of the Receivables Program,
the cash generated by collections on the Receivables was used to purchase,
among other things, additional Receivables originated by the Company. The
Company accounted for the Receivables Program as a financing transaction in
its consolidated financial statements.
Pursuant to the Receivables Program, the Company issued: (i) $175 million of
Floating Rate Class A Trade Receivables Participation Certificates, (ii) $35
million of Floating Rate Class B Trade Receivables Participation Certificates
and (iii) $90 million of Floating Rate Class A Trade Receivables Participation
Certificates Series 1997-1, which represent fractional undivided interests in
the Receivables and other assets of the master trust. The Certificates
28
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 4--Long-Term Debt--(continued)
each had a five-year term and bore interest at rates ranging from LIBOR plus
.2% to LIBOR plus .7%. In addition, the Company issued Floating Rate Revolving
Principal Trade Receivables Participation Certificates ("Revolving
Certificates"), pursuant to which investors could purchase up to $75 million
of interests in the master trust, which Certificates bore interest, at the
Company's option, at either LIBOR plus .35% or the federal funds rate plus
1.00%. There were no Revolving Certificates outstanding at September 30, 1998.
Restricted cash of $41.8 million at September 30, 1998, primarily represented
amounts temporarily deposited in the master trust which amounts were
designated for specific purposes pursuant to the Receivables Program,
including cash deposited by the Company to supplement the receivable
collateral base, if that base is not sufficient to support the Certificates.
Revolving Credit Facilities
In January 1997, the Company entered into a revolving credit agreement (the
"Credit Agreement") with a syndicate of senior lenders providing a senior
secured facility of $500 million. Among other things, the Credit Agreement:
(1) is for a term of five years, expiring in January 2002; (2) provides for
interest rates ranging from LIBOR plus 25 basis points to LIBOR plus 125 basis
points based upon certain financial ratios; (3) provides for the release of
security upon the attainment of certain financial ratios or once the Company
achieves investment grade senior, unsecured debt ratings from two credit
rating agencies; (4) provides for a borrowing base of 70% of the eligible
inventory; and (5) provides higher limits for possible acquisitions. An
extraordinary loss of $2.0 million (net of tax benefits of $1.3 million) was
recorded in fiscal 1997, representing the write-off of the unamortized
financing fees related to the retirement of the prior $380 million revolving
credit facility. In connection with the Credit Agreement, the Company incurred
approximately $3.0 million of financing fees which have been deferred and are
being amortized on a straight-line basis over the five-year term of the Credit
Agreement.
Revolving loans made under the Credit Agreement may be prepaid during its
term without premium and may subsequently be reborrowed. Commitments under the
Credit Agreement may be permanently reduced in full or in part at any time at
the option of the Company upon prior written notice.
Borrowings under the Credit Agreement bear interest at the rate of LIBOR
plus an applicable margin (.625% at September 30, 1999) or the applicable
prime rate. Interest on loans under the Credit Agreement is payable quarterly.
Under the terms of the Credit Agreement, the Company granted the senior
lenders a perfected first priority security interest in the Company's
inventory for collateral against borrowings under the Credit Agreement. The
Company is required to pay a commitment fee on the unused portion of
commitments under the Credit Agreement (.20% per annum at September 30, 1999)
plus an annual administration fee. At September 30, 1999, the $225.2 million
outstanding under the Credit Agreement bore interest at the rate of 6.1% per
annum.
As discussed in Note 2, the Company acquired C.D. Smith in July 1999, and
assumed $78 million in long-term debt. The assumed long-term debt was
immediately extinguished with funds provided by the Company's revolving credit
facility, resulting in an extraordinary charge in the fourth quarter of fiscal
1999 of approximately $2.8 million, net of income taxes of $1.6 million,
relating to prepayment penalties, the write-off of unamortized original issue
discount and the write-off of unamortized deferred financing fees.
For the fiscal years ended September 30, 1999 and 1998, C.D. Smith had a
revolving line of credit and certain term notes ("CDS Credit Facility") with a
group of lending institutions. Under the terms of the CDS Credit Facility,
which was due to expire in October 2000, C.D. Smith was able to borrow up to
approximately $90 million in addition to the amounts outstanding under the
term notes ($2.1 million at September 30, 1998 included in other debt), based
on eligible inventory and accounts receivable balances. Generally, advances
bore
29
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 4--Long-Term Debt--(continued)
interest at the lender's prime rate, payable monthly. The line of credit
borrowings amounted to $73.6 million at September 30, 1998.
Other Debt
In connection with its General Drug acquisition in October 1997, C.D. Smith
issued a subordinated note due and payable October 3, 2004 in the principal
amount of $12.0 million with a detachable common stock put warrant (see Note
5) to an investment group. This note was extinguished in July 1999 when C.D.
Smith merged with the Company as discussed above. Interest on the note of 12%
per annum was payable quarterly and principal installments of $1.8 million
were made in fiscal 1999. The estimated fair value of the warrant at the date
of issue in October 1997 was $2.6 million and was recorded as a discount on
the subordinated debt. The discount was being amortized to interest expense
over the seven-year term using the interest method and the unamortized
discount at September 30, 1998 was $2.0 million. At September 30, 1999, other
debt of $8.5 million primarily related to a mortgage note on a distribution
facility.
The Company enters into interest-rate cap agreements from time to time to
hedge the exposure to increasing interest rates with respect to its long-term
debt. The Company provides protection to meet actual interest rate exposures
and does not speculate in derivatives. The interest rate caps under these
agreements exceed the current market rates at the time they are entered into
and their cost is included in interest expense ratably over the life of the
agreement. The Company was required by its Credit Agreement to maintain
interest rate protection on a minimum of $112.5 million of its long-term debt
through January 1999. The Company entered into two-year interest rate cap
agreements which expired in May 1999 which specified that the 3-month LIBOR
base rate would not be greater than 7.50% with respect to $115 million of
borrowings under the Credit Agreement. The Company would have incurred
additional interest expense with respect to the borrowings if the LIBOR rate
had exceeded 7.5% and the other parties to the interest rate cap agreements
defaulted on their obligations under the agreements. During the term of the
interest rate cap agreement, the 3-month LIBOR rate did not exceed 7.5%.
The indentures governing the 1999 Securitization Facility and the Credit
Agreement contain restrictions and covenants which include limitations on
incurrence of additional indebtedness, restrictions on distributions and
dividends to stockholders, the repurchase of stock and the making of certain
other restricted payments, the issuance of preferred stock, the creation of
certain liens, transactions with subsidiaries and other affiliates, and
certain corporate acts such as mergers, consolidations, and the sale of
substantially all assets. Additional covenants require compliance with
financial tests, including leverage, fixed charge coverage, and maintenance of
minimum net worth.
Interest paid on the above indebtedness during the fiscal years ended
September 30, 1999, 1998, and 1997 was $39.0 million, $51.7 million, and $39.0
million, respectively.
Total amortization of financing fees and expenses (included in interest
expense) for the fiscal years ended September 30, 1999, 1998, and 1997 was
$2.4 million, $ 2.6 million, and $1.9 million, respectively.
As of September 30, 1999, the Company's revolving credit facility and
receivables securitization financing had fair values that approximated their
carrying amounts.
Note 5--Common Stock Put Warrant
The detachable common stock put warrant to purchase 415,267 shares of common
stock issued in connection with C.D. Smith's acquisition of General Drug in
October 1997, was exercised in July 1999 immediately prior to the Company's
acquisition of C.D. Smith. The exercise price was nominal and the fair value
30
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 5--Common Stock Put Warrant--(continued)
of the put warrant of $10.3 million was credited to capital in excess of par
value. Prior to its exercise, the fair value of this put warrant is presented
as a liability in the accompanying consolidated balance sheet due to the
holder's option to require settlement in cash. The Company recorded $0.3
million and $7.8 million in interest expense for the fiscal years ended
September 30, 1999 and 1998, respectively, to adjust the common stock put
warrant to its estimated fair value based on the implied value of C.D. Smith
prior to its acquisition by the Company. The fair value of the warrant at
September 30, 1998 was based upon a valuation prepared by an independent
investment company.
Note 6--Stockholders' Equity
The Company's earnings per share and share data in the financial statements
have been restated to reflect the effect of a two-for-one stock split in March
1999.
The holders of the Class A common stock are entitled to one vote per share
on all matters on which holders of Class A common stock are entitled to vote.
The holders of the Class A common stock may elect at any time to convert any
or all such shares into the Class B common stock on a share-for-share basis
(but only to the extent that such record holder of Class A common stock shall
be deemed to be required to convert such Class A common stock into Class B
common stock pursuant to applicable law).
The rights of holders of Class B and Class C common stock and holders of
Class A common stock are substantially identical and entitle the holders
thereof to the same rights, privileges, benefits, and notices, except that
holders of Class B and Class C common stock generally do not possess the right
to vote on any matters to be voted upon by the stockholders of the Company,
except as provided by law. Holders of Class B and Class C common stock may
elect at any time to convert any and all of such shares into Class A common
stock, on a share-for-share basis, to the extent the holder thereof is not
prohibited from owning additional voting securities by virtue of regulatory
restrictions.
The Class C common stock is subject to substantial restrictions on transfer
and has certain registration and "take-along" rights. A share of Class C
common stock will automatically be converted into a share of Class A common
stock (a) immediately prior to its sale in a future public offering or (b) at
such time as such share of Class C common stock has been sold publicly.
The following table (in thousands) is a reconciliation of the numerator and
denominator of the computation of earnings per share and earnings per share-
assuming dilution.
<TABLE>
<CAPTION>
Fiscal year ended
September 30,
-----------------------
1999 1998 1997
------- ------- -------
<S> <C> <C> <C>
Net income............................................. $67,466 $46,030 $48,141
Effect of dilutive warrant............................. 334 -- --
------- ------- -------
Net income--assuming dilution.......................... $67,800 $46,030 $48,141
======= ======= =======
Weighted average common shares outstanding............. 50,698 49,877 49,467
Effect of dilutive securities:
Options to purchase common stock...................... 666 836 834
Common stock put warrant.............................. 319 -- --
------- ------- -------
Weighted average common shares outstanding--assuming
dilution.............................................. 51,683 50,713 50,301
======= ======= =======
</TABLE>
The effect of the common stock put warrant in fiscal 1998 was anti-dilutive
and therefore, was not included in the above computation.
31
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 7--Pension and Other Benefit Plans
The Company provides a benefit for the majority of its employees under
noncontributory defined benefit pension plans. For each employee, the benefits
are based on years of service and average compensation. Pension costs, which
are computed using the projected unit credit cost method, are funded to at
least the minimum level required by government regulations.
The following table sets forth (in thousands) a reconciliation of the
changes in the Company sponsored defined benefit pension plans:
<TABLE>
<CAPTION>
Fiscal year ended
September 30,
------------------
1999 1998
-------- --------
<S> <C> <C>
Change in Benefit Obligations:
Benefit obligation at beginning of year.................... $ 56,714 $ 45,667
Service cost............................................... 4,089 3,034
Interest cost.............................................. 3,955 3,661
Amendments................................................. 125 161
Actuarial (gains)/losses................................... (3,489) 5,753
Benefit payments........................................... (2,446) (1,562)
-------- --------
Benefit obligation at end of year.......................... $ 58,948 $ 56,714
======== ========
Change in Plan Assets:
Fair value of plan assets at beginning of year............. $ 43,809 $ 37,266
Actual return on plan assets............................... 3,434 4,778
Employer contribution...................................... 4,415 3,886
Expenses................................................... (630) (559)
Benefit payments........................................... (2,446) (1,562)
-------- --------
Fair value of plan assets at end of year................... $ 48,582 $ 43,809
======== ========
Funded Status.............................................. $(10,365) $(12,905)
Unrecognized net actuarial (gain)/loss..................... 7,596 10,045
Unrecognized net obligation................................ (144) (315)
Unrecognized prior service cost............................ 2,671 2,917
-------- --------
Net amount recognized...................................... $ (242) $ (258)
======== ========
Amounts recognized in the statement of
financial position consist of:
Prepaid benefit cost...................................... $ (299) $ 926
Accrued benefit liability................................. (306) (1,805)
Intangible asset.......................................... 363 621
-------- --------
Net amount recognized...................................... $ (242) $ (258)
======== ========
</TABLE>
Assumptions used in computing the funded status of the plans were as
follows:
<TABLE>
<CAPTION>
1999 1998 1997
----- ------ ------
<S> <C> <C> <C>
Discount rate.............................................. 7.75% 7.00% 7.75%
Rate of increase in compensation levels.................... 6.25% 5.50% 6.25%
Expected long-term rate of return on assets................ 10.00% 10.00% 10.00%
</TABLE>
32
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 7--Pension and Other Benefit Plans--(continued)
The following table provides components of net periodic benefit cost for the
Company-sponsored defined benefit pension plans together with contributions
charged to expense for multi-employer union administered defined benefit
pension plans that the Company participates in (in thousands):
<TABLE>
<CAPTION>
Fiscal year ended
September 30,
----------------------
1999 1998 1997
------ ------ ------
<S> <C> <C> <C>
Components of net periodic benefit cost
Service cost - benefits earned during the period...... $4,098 $3,159 $2,994
Interest cost on projected benefit obligation......... 3,955 3,661 3,275
Expected return on plan assets........................ (4,554) (3,939) (3,406)
Amortization of net asset............................. (170) (170) (170)
Amortization of prior service cost.................... 371 369 359
Recognized net actuarial loss......................... 699 420 425
------ ------ ------
Net periodic pension cost of defined benefit pension
plan................................................. 4,399 3,500 3,477
Net pension cost of multi-employer plans.............. 454 419 245
------ ------ ------
Total pension expense................................ $4,853 $3,919 $3,722
====== ====== ======
</TABLE>
Plan assets at September 30, 1999 are invested principally in listed stocks,
corporate and government bonds, and cash equivalents. The projected benefit
obligation, accumulated benefit obligation, and fair value of plan assets for
pension plans with accumulated benefit obligations in excess of plan assets
were $3.9 million, $3.0 million, and $1.4 million, respectively, as of
September 30, 1999 and $3,941, $3,170, and $1,155, respectively, as of
September 30, 1998.
Defined Contribution Plans
The Company sponsors the Employee Investment Plan, a defined contribution
401(k) plan, which covers salaried and certain hourly employees. Eligible
participants may contribute to the plan from 2% to 18% of their regular
compensation before taxes. The Company matches the employee contributions up
to a maximum of 6% of their regular compensation in an amount equal to 50% of
the participants' contributions. An additional discretionary Company
contribution in an amount not to exceed 50% of the participants' contributions
may also be made depending upon the Company's performance. All contributions
are invested at the direction of the employee in one or more funds. Employer
contributions vest over a five-year period depending upon an employee's years
of service. In addition, as a result of its acquisition of C.D. Smith the
Company assumed a defined contribution 401(k) plan which covers substantially
all C.D. Smith employees with at least one year of service. Under the plan,
employees may elect to contribute a percentage of their annual salary subject
to Internal Revenue Code (IRC) maximum limitations. The plan provides for
employer matching and discretionary contributions, the amounts of which are to
be determined annually by the Board of Directors. During the 1999 plan year,
the Company matched 50% of employee contributions up to 4% of qualified
compensation. Costs of the defined contribution plans charged to expense for
the fiscal years ended September 30, 1999, 1998, and 1997 amounted to $1.4
million, $2.0 million, and $1.0 million, respectively.
Postretirement Benefit Obligations
As a result of special termination benefit packages previously offered, the
Company provides medical, dental, and life insurance benefits to only a
limited number of retirees and their dependents. These benefit plans are
unfunded. The accumulated postretirement benefit obligation was $0.5 million
as of September 30, 1999. The weighted average discount rate used in
determining the accumulated postretirement benefit obligations was 7.5% and
6.75% at September 30, 1999 and 1998, respectively. The annual expense for
such benefits is not material.
33
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 7--Pension and Other Benefit Plans--(continued)
Employee Stock Ownership Plan
As a result of its acquisition of C.D. Smith, the Company assumed the C.D.
Smith Healthcare, Inc. Employee Stock Ownership Plan ("ESOP"). The ESOP covers
substantially all employees of C.D. Smith with over one year of service who
are not associated with a collective bargaining unit. Under the ESOP, C.D.
Smith initially obtained a term loan from an outside bank in 1991 and
disbursed the proceeds to the ESOP in exchange for a note receivable for
purposes of acquiring shares from the original shareholders. Shares held as
collateral under the term loan are released each year in the proportion of
principal and interest paid in the current year to the principal and interest
remaining to be paid over the life of the loan. The Company is obligated to
make annual contributions sufficient to enable the ESOP to repay the loan with
interest at 0.5% below the prime rate. The ESOP owns approximately 1.8 million
shares of stock in the Company at September 30, 1999, of which 1.4 million
shares are allocated to ESOP participants. ESOP contributions totaling $0.1
million for each of the three years in the period ended September 30, 1999
were expensed. The loan and receivable are recorded in the Company's
consolidated balance sheets as long-term debt and a reduction in shareholders'
equity, respectively.
Note 8--Stock Option Plans
Effective October 1, 1996, the Company adopted the disclosure-only option
under SFAS No. 123, "Accounting for Stock-Based Compensation." The Company
continues to use the accounting method under APB Opinion No. 25 ("APB 25") and
related interpretations for its employee stock options. Under APB 25,
generally when the exercise price of the Company's employee stock options
equals the market price of the underlying stock on the date of grant, no
compensation expense is recognized.
During fiscal 1995, the Company adopted the AmeriSource Health Corporation
1995 Stock Option Plan (the "1995 Option Plan"), which provides for the
granting of nonqualified stock options to acquire up to approximately 2.4
million shares of common stock to employees of the Company at a price not less
than the fair market value of the common stock on the date the option is
granted. The option terms and vesting periods are determined at the date of
grant by a committee of the Board of Directors. Options expire six years after
the date of grant unless an earlier expiration date is set at the time of
grant.
During fiscal 1995, the Company also adopted the AmeriSource Health
Corporation Non-Employee Director Stock Option Plan (the "1995 Directors
Plan"), which provides for the grant of stock options to the Company's non-
employee directors. Under the 1995 Directors Plan, stock options are granted
annually at the fair market value of the Company's common stock on the date of
grant. The number of options so granted annually is fixed by the plan. Such
options become fully exercisable on the first anniversary of their respective
grant, except for the options under the initial grant, which are fully
exercisable on the third anniversary of the grant. The total number of shares
to be issued under the 1995 Directors Plan may not exceed 100,000 shares.
During fiscal 1997, the Company adopted the 1996 Employee Stock Option Plan
(the "1996 Option Plan") and the 1996 Non-Employee Directors Stock Option Plan
(the "1996 Directors Plan"). The 1996 Option Plan and the 1996 Directors Plan
provide for the granting of nonqualified stock options to acquire up to
1,594,000 and 100,000 shares of common stock, respectively, to employees and
non-employee directors at a price not less than the fair market value of the
common stock on the date the option is granted. The option terms and vesting
periods of the 1996 Option Plan are determined at the date of grant by a
committee of the Board of Directors. The number of options to be granted
annually under the 1996 Directors Plan is fixed by the plan and vest
immediately. Options expire ten years after the date of grant unless an
earlier expiration date is set at the time of grant.
34
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 8--Stock Option Plans--(continued)
During fiscal 1999, the Company assumed the C.D. Smith Drug Company 1996
Equity Compensation Plan pursuant to which options to purchase up to 2,000,000
shares of common stock may be granted to employees at a price not less than
the fair market value of the common stock on the date the option is granted.
The terms and vesting provisions of these options are determined by the Board
of Directors. Options expire ten years after the date of the grant. A total of
248,970 shares were reserved for issuance under the plan at the time of the
acquisition of C.D. Smith by AmeriSource. No further options will be granted
under this plan.
During fiscal 1999, the Company adopted the AmeriSource Health Corporation
1999 Stock Option Plan (the "1999 Option Plan") and the AmeriSource Health
Corporation 1999 Non-Employee Directors Stock Option Plan (the "1999 Directors
Plan"). The 1999 Option Plan and the 1999 Directors Plan provide for the
granting of nonqualified stock options to acquire up to 3,200,000 and 350,000
shares of common stock, respectively, at a price not less than the fair market
value of the common stock on the date the option is granted. The option terms
and vesting periods are determined at the date of grant by a committee of the
Board of Directors. The number of options to be granted annually under the
1999 Directors Plan is fixed by the plan and vest immediately. Options expire
ten years after the date of grant.
A summary of the Company's stock option activity for its option plans, and
related information for the fiscal years ended September 30 follows:
<TABLE>
<CAPTION>
1999 1998 1997
----------------- ----------------- ----------------
Weighted Weighted Weighted
Average Average Average
Options Exercise Options Exercise Options Exercise
(000) Price (000) Price (000) Price
------- -------- ------- -------- ------- --------
<S> <C> <C> <C> <C> <C> <C>
Outstanding beginning of
year....................... 3,127 $19 2,888 $14 2,614 $10
Granted................... 1,174 37 947 29 1,008 23
Exercised................. (604) 15 (549) 12 (347) 11
Forfeited................. (119) 25 (159) 15 (387) 16
------ ------ -----
Outstanding end of year..... 3,578 $25 3,127 $19 2,888 $14
====== ====== =====
Exercisable at end of year.. 1,534 $16 1,217 $12 992 $ 9
Weighted average fair value
of options granted during
the year................... $16.55 $12.16 $8.85
</TABLE>
A summary of the status of options outstanding at September 30, 1999
follows:
<TABLE>
<CAPTION>
Exercisable Options
Outstanding Options ---------------------------
-----------------------------------------------
Weighted
Average Weighted Weighted
Remaining Average Average
Exercise Number Contractual Exercise Number Exercise
Price Range (000) Life Price (000) Price
- ----------- ------ ----------- -------- ------ --------
<S> <C> <C> <C> <C> <C>
$ 1-$16 238 7 years $ 2 238 $ 2
$10-$14 812 1 year $12 720 $11
$20-$38 2,528 8 years $31 576 $28
</TABLE>
In December 1999, a grant of 969,550 stock options was made under the 1999
Option Plan.
Pro forma disclosures, as required by SFAS No. 123, regarding net income and
earnings per share have been determined as if the Company had accounted for
its employee stock options under the fair value method.
35
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 8--Stock Option Plans--(continued)
Option valuation models use highly subjective assumptions to determine the
fair value of traded options with no vesting or trading restrictions. Because
options granted under the Company's Stock Option Plans have vesting
requirements and cannot be traded, and because changes in the assumptions can
materially affect the fair value estimate, in management's opinion, the
existing valuation models do not necessarily provide a reliable measure of the
fair value of its employee stock options.
The fair values for the Company's options were estimated at the date of the
grant using a Black Scholes option pricing model with the following
assumptions for the years ending September 30, 1999, 1998 and 1997; a risk-
free interest rate ranging from 5.3% to 6.0%; no dividends; a volatility
factor of the expected market price of the Company's common stock ranging from
.392 to .407 and a weighted-average expected life of the options of 5 years.
For purposes of pro forma disclosures, the estimated fair value of the
options is amortized to expense over the options' assumed vesting period. SFAS
No. 123 requires only that the income effects of options granted since October
1, 1995 be included in the pro forma disclosures. Since a portion of the
Company's stock options vest over several years and additional options may be
granted each year, the pro forma effect on net income reported below is not
representative of the effect of fair value stock option expense on future
years' pro forma net income. The Company's pro forma information follows (in
thousands, except per share data):
<TABLE>
<CAPTION>
For the fiscal year
ended September 30,
-----------------------
1999 1998 1997
------- ------- -------
<S> <C> <C> <C>
Pro forma net income................................... $62,392 $42,971 $46,109
Pro forma earnings per share:
Basic................................................. $ 1.23 $ .86 $ .93
Assuming dilution..................................... 1.21 .85 .92
</TABLE>
Note 9--Leases
At September 30, 1999, future minimum payments totaling $52.8 million under
noncancelable operating leases with remaining terms of more than one fiscal
year were due as follows: 2000--$14.1 million; 2001--$11.2 million; 2002--$8.4
million; 2003--$5.1 million; 2004--$3.8 million; and thereafter--$10.1
million. In the normal course of business, operating leases are generally
renewed or replaced by other leases.
Total rental expense was $17.1 million in fiscal 1999, $14.9 million in
fiscal 1998, and $10.0 million in fiscal 1997.
Note 10--Facility Consolidations and Employee Severance
In connection with its acquisition of C.D. Smith, the Company began the
consolidation of one of C.D. Smith's pharmaceutical distribution facilities
into an existing AmeriSource distribution facility and the integration of C.D.
Smith pharmaceutical packaging business into AmeriSource's packaging operation
in the fourth quarter of fiscal 1999. In addition, the Company began to
incorporate the remaining two C.D. Smith facilities into the centralization
process described below. These efforts are expected to be completed by the end
of the second quarter of fiscal 2000.
36
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 10--Facility Consolidations and Employee Severance--(continued)
In the fourth quarter of fiscal 1998, the Company began to centralize its
data processing, accounting and contract administration functions, reorganize
its pharmaceutical distribution facilities into five regions, and consolidate
a pharmaceutical distribution facility into another facility. The
centralization process, which commenced in July 1998, is occurring on a
facility-by-facility basis and 15 of the original 19 facilities have been
centralized by the end of fiscal 1999. The centralization of three facilities
occurred in December 1999 and the centralization of the remaining facility has
been rescheduled to the third quarter of fiscal 2000 following the C.D. Smith
centralizations.
In the third quarter of fiscal 1997, the Company commenced cost reduction
plans to consolidate three of its pharmaceutical distribution facilities into
other existing facilities and restructure its sales force. These initiatives
were completed in fiscal 1998. In addition, the Company incurred costs related
to the retirement of its former President and CEO as well as other executive
terminations during fiscal 1997.
The cost reduction initiatives referred to above resulted in the following
charges for the fiscal year ended September 30 (in thousands):
<TABLE>
<CAPTION>
1999 1998 1997
------- ------ -------
<S> <C> <C> <C>
Write-downs of assets................................... $ 6,400 $2,168 $ 3,857
Severance............................................... 1,857 3,269 1,832
Contract and lease cancellations and other.............. 3,473 2,846 727
Executive severance..................................... -- -- 5,155
------- ------ -------
$11,730 $8,283 $11,571
======= ====== =======
</TABLE>
Write-downs of assets in fiscal 1999 primarily relates to the write-off of
goodwill for the consolidated facility as well as the estimated loss on the
sale of the facility. Write-downs of assets in 1998 relate primarily to
computer equipment to be abandoned as a result of the data processing
centralization. In fiscal 1997, write-downs of assets related to buildings,
warehouse and computer equipment and other assets to be disposed of primarily
due to the facility consolidations. The write-downs of assets were based on
estimated salvage and market values of related facilities and equipment
compared to carrying values. Computer and warehouse equipment were determined
to have minimal salvage value based on Company estimates.
Severance includes the termination of approximately 90 and 350
administrative and warehouse employees in fiscal 1999 and 1998, respectively,
and 240 warehouse and sales employees in fiscal 1997. All of the employees
targeted in fiscal 1997, were terminated by September 30, 1999. Approximately
85 and 80 of the employees targeted in fiscal 1999 and 1998, respectively,
have not yet been terminated as of September 30, 1999. Accrued severance of
$3.1 million and $4.3 million, including executive severance of $0.4 million
and $1.4 million, at September 30, 1999 and 1998, respectively, is included in
accrued expenses and other.
Contract and lease cancellations and other in fiscal 1999 relates primarily
to the expected termination costs of a non-cancellable supply contract arising
from the C.D. Smith acquisition. The Company's obligations under this contract
are subject to an arbitration which will be held in fiscal 2000. Contract and
lease cancellations and other in fiscal 1998 relates primarily to non-
cancellable lease obligations remaining after the conversion dates for
computer equipment to be abandoned as a result of the data processing
centralization. In fiscal 1997, contract and lease cancellations and other
relates primarily to non-cancellable lease obligations of the consolidated
facilities. Remaining lease obligations of $4.3 million and $3.0 million are
included in accrued expenses and other at September 30, 1999 and 1998.
In the fourth quarter of fiscal 1999, accruals established in fiscal 1997
related to asset write-downs and severance were adjusted by $0.8 million and
$0.3 million, respectively, and are netted against the fiscal 1999 facility
consolidations and employee severance charge.
37
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 11--Legal Matters and Contingencies
In the ordinary course of its business, the Company becomes involved in
lawsuits, administrative proceedings, and governmental investigations,
including antitrust, environmental, product liability, and regulatory agency
and other matters. In some of these proceedings, plaintiffs may seek to
recover large and sometimes unspecified amounts and the matters may remain
unresolved for several years. On the basis of information furnished by counsel
and others, the Company does not believe that these matters, individually or
in the aggregate, will have a material adverse effect on its business or
financial condition.
In 1998 the Company sued a former customer which refused to pay invoices,
net of credit memos, totaling approximately $21 million for goods sold and
delivered. The former customer has filed counterclaims alleging it suffered
damages as a result of certain performance problems affecting the Company. The
Company believes there is no merit to these counterclaims and is aggressively
pursuing collection of the outstanding amount. A trial is scheduled for
January 2000 and ultimate collectibility of amounts owed to the Company is
dependent on the outcome of the trial and the continued creditworthiness of
the former customer.
In November 1993, the Company was named a defendant, along with six other
wholesale distributors and twenty-four pharmaceutical manufacturers, in a
series of purported class action antitrust lawsuits brought by retail
pharmacies and alleging violations of various antitrust laws stemming from the
use of chargeback agreements. In addition, the Company and four other
wholesale distributors were added as defendants in a series of related
antitrust lawsuits brought by independent pharmacies and chain drug stores,
both of which opted out of the class cases. The Company also was named a
defendant in parallel suits filed in state courts in Minnesota, Alabama,
Tennessee and Mississippi. The federal class actions were originally filed in
the United States District Court for the Southern District of New York, but
were transferred along with the individual and chain drug store cases to the
United States District Court for the Northern District of Illinois. Plaintiffs
seek injunctive relief, treble damages, attorneys' fees and costs. In October
1994, the Company entered into a Judgment Sharing Agreement with the other
wholesaler and pharmaceutical manufacturer defendants. Under the Judgment
Sharing Agreement: (a) the manufacturer defendants agreed to reimburse the
wholesaler defendants for litigation costs incurred up to an aggregate of $9
million; and (b) if a judgment is entered against both manufacturers and
wholesalers, the total exposure for joint and several liability of the Company
is limited to the lesser of 1% of such judgment or $1 million. In addition,
the Company has released any claims which it might have had against the
manufacturers for the claims presented by the plaintiffs in these lawsuits.
Subsequent amendments to the Judgment Sharing Agreement have provided
additional protection to the Company from litigation expenses in exchange for
updated releases. The Judgment Sharing Agreement covers the federal court
litigation as well as the cases which have been filed in various state courts.
On April 4, 1996, the District Court granted the Company's motion for
summary judgment in the class case. Plaintiffs subsequently appealed the
Company's grant of summary judgment to the United States Seventh Circuit Court
of Appeals. On August 15, 1997, the Court of Appeals reversed the District
Court's order granting summary judgment in favor of the Company and the other
wholesalers. The Court of Appeals also denied the Company's petition for
rehearing. The Company and the other wholesalers filed a petition for a writ
of certiorari to the United States Supreme Court; the petition was denied.
Trial in the class case commenced in the United States District Court for the
Northern District of Illinois on September 23, 1998. After a ten-week trial,
the Court granted all of the defendants motions for a directed verdict and
dismissed the claims the class plaintiffs had asserted against the Company and
the other defendants. Plaintiffs in the class case then appealed the District
Court's judgment to the Seventh Circuit Court of Appeals. On June 9, 1999, the
Seventh Circuit affirmed the judgment the District Court entered in favor of
the Company in the class case. Plaintiffs have filed a petition for a writ of
certiorari to the United States Supreme Court; that petition is pending.
38
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 11--Legal Matters and Contingencies--(continued)
The state cases are proceeding. The Minnesota case settled without any
payment or admission of liability by the Company. On November 29, 1999, the
trial court in Alabama dismissed all of the claims asserted against the
Company and the other wholesaler and manufacturer defendants pending in
accordance with a ruling from the Alabama Supreme Court. The Mississippi and
Tennessee cases remain, though there has been very little activity in either
forum.
On or about October 2, 1997, a group of retail chain drug stores and
individual pharmacies, both of which had opted out of the class cases, filed a
motion with the United States District Court for the Northern District of
Illinois seeking to add the Company and the other wholesale distributors as
defendants in their cases against the manufacturer defendants, which cases are
consolidated before the same judge who presides over the class case. This
motion was granted and the Company and the other wholesale distributors have
been added as defendants in those cases as well. As a result, the Company has
been served with approximately 120 additional complaints on behalf of
approximately 4,000 pharmacies and chain retailers. Discovery and motion
practice is presently underway in all of these opt-out cases. The Company
believes it has meritorious defenses to the claims asserted in these lawsuits
and intends to vigorously defend itself in all of these cases.
The Company is subject to contingencies pursuant to environmental laws and
regulations at one of its former distribution centers that may require the
Company to take remediation efforts. In fiscal 1994, the Company accrued $4.1
million to cover future consulting, legal, and remediation and ongoing
monitoring costs. The accrued liability, which is reflected in other
liabilities in the accompanying consolidated balance sheet ($3.8 million at
September 30, 1999), is based on an engineering analysis prepared by outside
consultants and represents an estimate of the extent of contamination and
choice of remedy based on existing technology and presently enacted laws and
regulations. However, changes in remediation standards, improvements in
cleanup technology and discovery of additional information concerning the site
could affect the estimated liability in the future.
Note 12--Merger Costs
In connection with its acquisition of C.D. Smith in the fourth quarter of
fiscal 1999, the Company expensed merger related costs of $3.2 million
consisting primarily of investment banking, accounting, and legal fees.
In fiscal 1998, the Company and McKessonHBOC jointly terminated a definitive
merger agreement signed in September 1997 after the Federal Trade Commission
obtained an injunction halting the proposed merger. Merger related costs
consisting of professional fees and stay-put bonuses totaling $18.4 million
were expensed in the fourth quarter of fiscal 1998 as a result of the
termination of the merger agreement.
39
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Note 13--Quarterly Financial Information (Unaudited)
QUARTERLY FINANCIAL DATA
(in thousands, except per share data)
<TABLE>
<CAPTION>
Three months ended
------------------------------------------------
December 31, March 31, June 30, September 30,
1998 1999 1999 1999
------------ ---------- ---------- -------------
<S> <C> <C> <C> <C>
Operating revenue............. $2,362,648 $2,372,872 $2,455,797 $2,568,766
Bulk deliveries to customer
warehouses................... 12,087 12,299 12,740 10,154
---------- ---------- ---------- ----------
Total revenue................. 2,374,735 2,385,171 2,468,537 2,578,920
Gross profit.................. 111,126 122,986 113,025 125,928
Selling and administrative
expenses, depreciation and
amortization................. 71,462 76,506 71,558 94,537
Operating income.............. 39,664 46,480 41,467 31,391
Income before extraordinary
item......................... 17,895 20,219 21,760 11,041
Extraordinary item--early
retirement of debt........... -- -- -- (3,449)
Net income.................... 17,895 20,219 21,760 7,592
Earnings per share:
Income before extraordinary
item....................... .36 .40 .43 .22
Extraordinary item.......... -- -- -- (.07)
Net income................ .36 .40 .43 .15
Earnings per share--assuming
dilution:
Income before extraordinary
item....................... .35 .39 .39 .21
Extraordinary item.......... -- -- -- (.07)
Net income................ .35 .39 .39 .15*
</TABLE>
- --------
*Difference due to rounding.
<TABLE>
<CAPTION>
Three months ended
------------------------------------------------
December 31, March 31, June 30, September 30,
1997 1998 1998 1998
------------ ---------- ---------- -------------
<S> <C> <C> <C> <C>
Operating revenue............. $2,451,096 $2,398,897 $2,295,110 $2,228,379
Bulk deliveries to customer
warehouses................... 29,225 36,372 41,191 22,767
---------- ---------- ---------- ----------
Total revenue................. 2,480,321 2,435,269 2,336,301 2,251,146
Gross profit.................. 115,755 123,605 109,512 113,025
Selling and administrative
expenses, depreciation and
amortization................. 75,217 80,711 70,341 96,697
Operating income.............. 40,538 42,894 39,171 16,328
Net income.................... 15,689 17,397 11,217 1,727
Net income per share.......... .32 .35 .22 .03
Net income per share--assuming
dilution..................... .31 .34 .22 .03
</TABLE>
In the fourth quarter of fiscal 1999, the Company incurred a $11.7 million
charge to consolidate a facility and centralize administrative functions in
connection with its acquisition of C.D. Smith (see Note 10). It also incurred
$3.2 million of merger costs in connection with the acquisition. See Note 12.
In the fourth quarter of fiscal 1998, the Company recorded $18.4 million in
costs related to the termination of its merger agreement with McKessonHBOC
(see Note 12) as well as $8.3 million for restructuring initiatives undertaken
to centralize redundant administrative functions, and to close a distribution
facility. See Note 10.
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.
(No response to this Item is required.)
40
<PAGE>
Part III
Item 10. Directors and Executive Officers of the Registrant.
Information appearing under "Election of Directors" and "Compliance with
Section 16(a) of the Securities Exchange Act of 1934" in the Company's Notice
of Annual Meeting of Stockholders and Proxy Statement for the 2000 annual
meeting of stockholders (the "2000 Proxy Statement") is incorporated herein by
reference. The Company will file the 2000 Proxy Statement with the Commission
pursuant to Regulation 14A within 120 days after the close of the fiscal year.
Information regarding executive officers is set forth in Part I of this
report.
Item 11. Executive Compensation.
Information regarding executive compensation appearing under "Management,"
"Compensation of Directors," "Compensation Committee Interlocks and Insider
Participation," "Report of the Compensation Committee of the Board of
Directors," and "Stockholder Return Performance" in the 2000 Proxy Statement
is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management.
Information regarding security ownership of certain beneficial owners and
management appearing under "Security Ownership of Certain Beneficial Owners
and Management" in the 2000 Proxy Statement is incorporated herein by
reference.
Item 13. Certain Relationships and Related Transactions.
Information appearing under "Certain Relationships and Transactions" in the
2000 Proxy Statement is incorporated herein by reference.
Part IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K.
(a)(1) and (2) List of Financial Statements and Schedules.
Financial Statements: The following consolidated financial statements are
submitted in response to Item 14(a)(1):
<TABLE>
<CAPTION>
Page
----
<S> <C>
Report of Ernst & Young LLP, Independent Auditors......................... 18
Consolidated Balance Sheets as of September 30, 1999 and 1998............. 19
Consolidated Statements of Operations for the fiscal years ended September
30, 1999, 1998 and 1997.................................................. 21
Consolidated Statements of Changes in Stockholders' Equity for the fiscal
years ended September 30, 1999, 1998 and 1997............................ 22
Consolidated Statements of Cash Flows for the fiscal years ended September
30, 1999, 1998 and 1997.................................................. 23
Notes to Consolidated Financial Statements................................ 24
</TABLE>
Financial Statement Schedules: The following financial statement schedules
are submitted in response to Item 14(a)(2) and Item 14(d):
<TABLE>
<S> <C>
Schedule I--Condensed Financial Information of AmeriSource Health
Corporation as of
September 30, 1999 and 1998 and for the fiscal years ended
September 30, 1999, 1998 and 1997................................ S-1
Schedule II--Valuation and Qualifying Accounts............................ S-4
</TABLE>
All other schedules for which provision is made in the applicable accounting
regulations of the Securities and Exchange Commission are not required under
the related instructions or are inapplicable and, therefore, have been
omitted.
41
<PAGE>
(a)(3) List of Exhibits.*
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<C> <S>
2 Amended and Restated Agreement and Plan of Reorganization by and among
AmeriSource Health Corporation, Hawk Acquisition Corp., C.D. Smith
Healthcare, Inc. and a Person to be Designated Escrow Agent, dated as
of April 28, 1999, as amended and restated as of May 27, 1999
(incorporated by reference to Exhibit 2 to the Registrant's
Registration Statement on Form S-4, Registration No. 333-79591, filed
May 28, 1999).
3.1 Restated Certificate of Incorporation of the Company, as amended
(incorporated by reference to Exhibit 3.1 to Amendment No. 1 to the
Registrant's Registration Statement on Form S-4, Registration No. 333-
79591, filed June 8, 1999).
3.2 Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the
Company's Registration Statement on Form S-1, Amendment No. 1 (SEC
File No. 33-44244)).
4.1 Receivables Purchase Agreement, dated as of December 13, 1994 between
AmeriSource, as Seller and AmeriSource Receivables Corporation, as
Purchaser (incorporated by reference to Exhibit 4.11 to Registrant's
Annual Report on Form 10-K for the fiscal year ended September 30,
1994).
4.2 AmeriSource Receivables Master Trust Pooling and Servicing Agreement,
dated as of December 13, 1994 among AmeriSource Receivables
Corporation, as transferor, AmeriSource, as the initial Servicer, and
Manufacturers and Traders Trust Company, as Trustee (incorporated by
reference to Exhibit 4.12 to Registrant's Annual Report on Form 10-K
for the fiscal year ended September 30, 1994).
4.3 Revolving Certificate Purchase Agreement, dated as of December 13,
1994 among AmeriSource Receivables Corporation, AmeriSource, The
Revolving Purchasers and Bankers Trust Company, as Agent and Revolving
Purchaser (incorporated by reference to Exhibit 4.13 to Registrant's
Annual Report on Form 10-K for the fiscal year ended September 30,
1994).
4.4 Series 1994-1 Supplement to Pooling and Servicing Agreement, dated as
of December 13, 1994 among AmeriSource Receivables Corporation, as
Transferor, AmeriSource, as Initial Servicer, and Manufacturers and
Traders Trust Company, as Trustee (incorporated by reference to
Exhibit 4.14 to Registrant's Annual Report on Form 10-K for the fiscal
year ended September 30, 1994).
4.5 Credit Agreement, dated as of January 8, 1997 among AmeriSource
Corporation as Borrower, AmeriSource Health Corporation and Certain
Subsidiaries and Affiliates, as Guarantors and Nations Bank, N.A. as
Administrative Agent (incorporated by reference to Exhibit 4.14 to
Registrant's Quarterly Report Form 10-Q for its fiscal quarter ended
December 31, 1996).
4.6 Amendment No. 1, dated as of February 26, 1997 to the January 1997
Credit Agreement (incorporated by reference to Exhibit 4.15 to
Registrant's Quarterly Report on Form 10-Q for its fiscal quarter
ended March 31, 1997).
4.7 Amendment to Pooling and Servicing Agreement and Receivables Purchase
Agreement, dated as of March 5, 1997 among AmeriSource Receivables
Corporation, AmeriSource Corporation, and Manufacturers and Traders
Trust Company, as Trustee (incorporated by reference to Exhibit 4.1 to
Registrant's Quarterly Report on Form 10-Q for its fiscal quarter
ended June 30, 1997).
4.8 Certificate Purchase Agreement, dated as of April 11, 1997, among
AmeriSource Corporation, AmeriSource Receivables Corporation, BT
Securities Corporation, Bankers Trust International PLC, and Bankers
Trust Australia Limited (incorporated by reference to Exhibit 4.2 to
Registrant's Quarterly Report on Form 10-Q for its fiscal quarter
ended June 30, 1997).
4.9 Amendment to Pooling and Servicing Agreement and Receivables Purchase
Agreement dated as of April 17, 1997 among AmeriSource Receivables
Corporation, AmeriSource Corporation, and Manufacturers and Traders
Trust Company, as Trustee (incorporated by reference to Exhibit 4.3 to
Registrant's Quarterly Report on Form 10-Q for its fiscal quarter
ended June 30, 1997).
</TABLE>
42
<PAGE>
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<C> <S>
4.10 Series 1997-1 Supplement to Pooling and Servicing Agreement dated as
of April 17, 1997 among AmeriSource Receivables Corporation as
Transferor, AmeriSource Corporation as initial Servicer and
Manufacturers and Traders Trust Company as Trustee (incorporated by
reference to Exhibit 4.4 to Registrant's Quarterly Report on Form 10-Q
for its fiscal quarter ended June 30, 1997).
4.11 Amendment No. 3, dated October 1997, to the January 1997 Credit
Agreement (incorporated by reference to Exhibit 4.15 to Registrant's
Annual Report on Form 10-K for the fiscal year ended September 30,
1998).
4.12 Amendment No. 4, dated November 1998, to the January 1997 Credit
Agreement (incorporated by reference to Exhibit 4.17 to the
Registrant's Annual Report on Form 10-K for the fiscal year ended
September 30, 1998).
4.13 Receivables Purchase Agreement among AmeriSource Receivables Financial
Corporation, as Seller, AmeriSource Corporation, as Guarantor,
Delaware Funding Corporation, as Buyer, and Morgan Guaranty Trust
Company of New York, as Administrative Agent, dated as of May 14, 1999
(incorporated by reference to Exhibit 4.13 to the Registrant's
Registration Statement on Form S-4, Registration No. 333-79591, filed
May 28, 1999).
4.14 Purchase Agreement between AmeriSource Corporation, as Seller, and
AmeriSource Receivable Financial Corporation, as Payer, dated as of
May 14, 1999 (incorporated by reference to Exhibit 4.14 to the
Registrant's Registration Statement on Form S-4, Registration No. 333-
79591, filed May 28, 1999).
10.1 AmeriSource Master Pension Plan (incorporated by reference to Exhibit
10.9 to Registration Statement on Form S-1, Registration No. 33-27835,
filed March 29, 1989).
10.2 AmeriSource 1988 Supplemental Retirement Plan (incorporated by
reference to Exhibit 10.10 to the Registration Statement on Form S-1,
Registration No. 33-27835, filed March 29, 1989).
10.3 Form of Take-Along and Registration Rights Agreement between
Registrant and Citicorp Venture Capital Ltd. (incorporated by
reference to Exhibit 4.19 to Amendment No. 2, filed September 7, 1989,
to the Registration Statement on Form S-1, Registration No. 33-27835).
10.4 Agreement, dated October 14, 1994, among certain manufacturers and
wholesalers of prescription products, including AmeriSource
(incorporated by reference to Exhibit 10.13 to Registrant's Annual
Report on Form 10-K for the fiscal year ended September 30, 1994).
10.5 Registrant's 1995 Stock Option Plan (incorporated by reference to
Exhibit 10.16 to Amendment No. 2 to the Registrant's Registration
Statement on Form S-2 dated April 3, 1995, Registration No. 33-57513).
10.6 Registrant's Non-Employee Directors Stock Option Plan (incorporated by
reference to Exhibit 10.17 to Amendment No. 2 to the Registrant's
Registration Statement on Form S-2 dated April 3, 1995, Registration
No. 33-57513).
10.7 Employment Agreement, dated September 4, 1997, between AmeriSource and
R. David Yost (incorporated by reference to Exhibit 10.12 to
Registrant's Annual Report on Form 10-K for the fiscal year ended
September 30, 1997).
10.8 Employment Agreement, dated September 4, 1997, between AmeriSource and
David M. Flowers (incorporated by reference to Exhibit 10.13 to
Registrant's Annual Report on Form 10-K for the fiscal year ended
September 30, 1997).
10.9 Employment Agreement, dated September 4, 1997, between AmeriSource and
Kurt J. Hilzinger (incorporated by reference to Exhibit 10.14 to
Registrant's Annual Report on Form 10-K for the fiscal year ended
September 30, 1997).
10.10 AmeriSource Health Corporation 1996 Stock Option Plan (incorporated by
reference to Appendix C to Registrant's Proxy Statement dated January
15, 1997 for the Annual Meeting of Stockholders held on February 11,
1997).
</TABLE>
43
<PAGE>
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<C> <S>
10.11 AmeriSource Health Corporation 1996 Non-Employee Directors Stock
Option Plan (incorporated by reference to Appendix D to Registrant's
Proxy Statement dated January 15, 1997 for the Annual Meeting of
Stockholders held on February 11, 1997).
10.12 1996 Amendment to the AmeriSource Health Corporation 1995 Stock Option
Plan (incorporated by reference to Appendix A to Registrant's Proxy
Statement dated January 15, 1997 for the Annual Meeting of
Stockholders held on February 11, 1997).
10.13 Consulting Agreement, dated October 31, 1997, between AmeriSource
Corporation and John F. McNamara (incorporated by reference to Exhibit
10.18 to Registrant's Annual Report on Form 10-K for the fiscal year
ended September 30, 1997).
10.15 Form of Voting/Support Agreement among AmeriSource Health Corporation,
Hawk Acquisition Corp. and certain executives of C.D. Smith
(incorporated by reference to Exhibit 10.15 to the Registrant's
Registration Statement on Form S-4, Registration No. 333-79591, filed
May 28, 1999).
10.16 Form of Voting/Support Agreement among AmeriSource Health Corporation,
Hawk Acquisition Corp. and Churchill ESOP Capital Partners
(incorporated by reference to Exhibit 10.16 to the Registrant's
Registration Statement on Form S-4, Registration No. 333-79591, filed
May 28, 1999).
10.17 C.D. Smith Healthcare, Inc. Employee Stock Ownership Plan, dated
January 1, 1987, as restated on December 10, 1991 (incorporated by
reference to Exhibit 10.17 to the Registrant's Registration Statement
on Form S-4, Registration No. 333-79591, filed May 28, 1999).
10.18 Amendment, dated October 1, 1992 to the C.D. Smith Healthcare, Inc.
Employee Stock Ownership Plan (incorporated by reference to Exhibit
10.18 to the Registrant's Registration Statement on Form S-4,
Registration No. 333-79591, filed May 28, 1999).
10.19 Amendment, dated December 2, 1994, to the C.D. Smith Healthcare, Inc.
Employee Stock Ownership Plan (incorporated by reference to Exhibit
10.19 to Amendment No. 1 to the Registrant's Registration Statement on
Form S-4, Registration No. 333-79591, filed June 8, 1999).
10.20 Amendment, dated October 1, 1996, to the C.D. Smith Healthcare, Inc.
Employee Stock Ownership Plan (incorporated by reference to Exhibit
10.20 to Amendment No. 1 to the Registrant's Registration Statement on
Form S-4, Registration No. 333-79591, filed June 8, 1999).
10.21 Amendment, dated January 1, 1998, to the C.D. Smith Healthcare, Inc.
Employee Stock Ownership Plan (incorporated by reference to Exhibit
10.21 to Amendment No. 1 to the Registrant's Registration Statement on
Form S-4, Registration No. 333-79591, filed June 8, 1999).
10.22 AmeriSource Health Corporation 1999 Non-Employee Directors Stock
Option Plan (incorporated by reference to Appendix C to Registrant's
Proxy Statement dated February 5, 1999 for the Annual Meeting of
Stockholders held on March 3, 1999).
21 Subsidiaries of the Registrant.
23 Consent of Ernst & Young LLP.
27 Financial Data Schedule for the year ended September 30, 1999.
27.1 Financial Data Schedule for the years ended September 30, 1998 and
September 30, 1997. Restated for the acquisition of C.D. Smith
accounted for as a pooling-of-interests.
99 Not Applicable.
</TABLE>
- --------
* Copies of the exhibits will be furnished to any security holder of the
Registrant upon payment of the reasonable cost of reproduction.
(b) Reports on Form 8-K
None.
44
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
AmeriSource Health Corporation
/s/ George L. James III
Date: December 28, 1999 By: _________________________________
(George L. James III) Vice
President and Chief Financial
Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below on December 28, 1999 by the following persons on
behalf of the Registrant and in the capacities indicated.
Signature Title
/s/ R. David Yost President and Chief
- ------------------------------------- Executive Officer
(R. David Yost) and Director
(Principal
Executive Officer)
/s/ George L. James III Vice President and
- ------------------------------------- Chief Financial
(George L. James III) Officer (Principal
Financial Officer)
/s/ Michael D. DiCandilo Vice President,
- ------------------------------------- Controller
(Michael D. DiCandilo) (Principal
Accounting Officer)
Director
- -------------------------------------
(Bruce C. Bruckmann)
/s/ Michael A. Delaney Director
- -------------------------------------
(Michael A. Delaney)
/s/ Richard C. Gozon Director
- -------------------------------------
(Richard C. Gozon)
/s/ Lawrence C. Karlson Director and
- ------------------------------------- Chairman
(Lawrence C. Karlson)
/s/ George H. Strong Director
- -------------------------------------
(George H. Strong)
/s/ Edward E. Hagenlocker Director
- -------------------------------------
(Edward E. Hagenlocker)
Director
- -------------------------------------
(Barton J. Winokur)
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
SCHEDULE I--CONDENSED FINANCIAL INFORMATION OF REGISTRANT
AMERISOURCE HEALTH CORPORATION
CONDENSED BALANCE SHEETS
(dollars in thousands, except per share data)
<TABLE>
<CAPTION>
September 30,
------------------
1999 1998
-------- --------
ASSETS
<S> <C> <C>
Cash...................................................... $ 59 $ 3
Receivable from AmeriSource Corporation................... 43,728 35,234
Other assets ............................................. 119 230
Investment at equity in AmeriSource Corporation (accumu-
lated gains and losses of AmeriSource in excess of in-
vestment)................................................ 122,472 50,631
-------- --------
$166,378 $ 86,098
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Accrued expenses.......................................... $ 101 $ 358
Common stock put warrant.................................. -- 10,385
Stockholders' equity:
Common Stock, $.01 par value
Class A (voting and convertible):
50,000,000 shares authorized; issued 9/99--51,737,893
shares; 9/98-- 46,582,950 shares..................... 517 466
Class B (nonvoting and convertible):
15,000,000 shares authorized; issued 9/99--5,908,445
shares; 9/98-- 11,401,566 shares..................... 59 114
Class C (nonvoting and convertible):
2,000,000 shares authorized; issued 9/99--165,936
shares; 9/98--258,474 shares......................... 2 2
Capital in excess of par value.......................... 266,737 244,556
Accumulated deficit..................................... (94,632) (162,098)
Cost of common stock in treasury........................ (6,220) (7,353)
Note receivable from ESOP............................... (186) (332)
-------- --------
166,277 75,355
-------- --------
$166,378 $ 86,098
======== ========
</TABLE>
See notes to condensed financial statements.
S-1
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
SCHEDULE I--CONDENSED FINANCIAL INFORMATION OF REGISTRANT
AMERISOURCE HEALTH CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
<TABLE>
<CAPTION>
Fiscal Year Ended
September 30,
------------------------
1999 1998 1997
------- ------- -------
<S> <C> <C> <C>
Equity in net income of subsidiary before
extraordinary items................................. $70,915 $46,030 $50,123
Extraordinary items--early retirement of debt, net of
income tax benefits................................. (3,449) -- (1,982)
------- ------- -------
Net income........................................ $67,466 $46,030 $48,141
======= ======= =======
Earnings per share:
Income before extraordinary items.................. $ 1.40 $ .92 $ 1.01
Extraordinary items................................ (.07) -- (.04)
------- ------- -------
Net income....................................... $ 1.33 $ .92 $ .97
======= ======= =======
Earnings per share--assuming dilution:
Income before extraordinary items.................. $ 1.38 $ .91 $ 1.00
Extraordinary items................................ (.07) -- (.04)
------- ------- -------
Net income....................................... $ 1.31 $ .91 $ .96
======= ======= =======
Weighted average common shares outstanding:
Basic.............................................. 50,698 49,877 49,467
Assuming dilution.................................. 51,683 50,713 50,301
</TABLE>
---------------
CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)
<TABLE>
<CAPTION>
Fiscal Year Ended
September 30,
--------------------------
1999 1998 1997
------- ------- --------
<S> <C> <C> <C>
OPERATING ACTIVITIES
Net income........................................ $67,466 $46,030 $ 48,141
Adjustments to reconcile net income to net cash
used in operating activities:
Equity in net income of subsidiary.............. (70,915) (46,030) (50,123)
Adjustment of common stock put warrant to fair
value.......................................... 334 7,816 --
Changes in operating assets and liabilities:
Receivable from AmeriSource Corporation......... (4,436) (2,888) (1,988)
Accrued expenses................................ (257) 14 --
Miscellaneous................................... 143 22 14
------- ------- --------
NET CASH (USED IN) PROVIDED BY OPERATING
ACTIVITIES................................... (7,665) 4,964 (3,956)
FINANCING ACTIVITIES
Exercise of stock options and warrant............. 8,981 6,682 3,809
Purchases of treasury stock....................... (449) (180) (201)
------- ------- --------
NET CASH PROVIDED BY FINANCING ACTIVITIES..... 8,532 6,502 3,608
INVESTING ACTIVITIES
Capital contribution, net......................... (811) (11,465) 341
------- ------- --------
NET CASH (USED IN) PROVIDED BY INVESTING
ACTIVITIES................................... (811) (11,465) 341
------- ------- --------
INCREASE (DECREASE) IN CASH........................ 56 1 (7)
Cash at beginning of year.......................... 3 2 9
------- ------- --------
CASH AT END OF YEAR................................ $ 59 $ 3 $ 2
======= ======= ========
</TABLE>
See notes to condensed financial statements.
S-2
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
SCHEDULE-I CONDENSED FINANCIAL INFORMATION OF REGISTRANT
NOTES TO CONDENSED FINANCIAL STATEMENTS
Note 1--Summary of Significant Accounting Policies
The accompanying condensed financial statements present the financial
position, results of operations and cash flows of AmeriSource Health
Corporation (the "Company") as of the dates and for the periods indicated in
accordance with Rule 12-04 of Regulation S-X of the Securities Exchange Act of
the Securities and Exchange Commission and, accordingly, do not include the
accounts of its wholly-owned subsidiaries. The Company's primary asset is its
investment in and receivables from AmeriSource Corporation, which is a wholly-
owned subsidiary of the Company. Substantially all of the Company's operations
are transacted by AmeriSource Corporation. The ability of the Company to pay
its obligations depends on the operations of AmeriSource Corporation.
These condensed financial statements should be read in conjunction with the
Consolidated Financial Statements of AmeriSource Health Corporation and
Subsidiaries contained in Item 8 of this document for more information on
long-term debt, stockholders' equity and other disclosures.
S-3
<PAGE>
AMERISOURCE HEALTH CORPORATION AND SUBSIDIARIES
SCHEDULE II--VALUATION AND QUALIFYING ACCOUNTS
<TABLE>
- --------------------------------------------------------------------------------
<CAPTION>
Col. A Col. B Col. C Col. D Col. E
- ---------------------------------------------------------------------------------------
Additions
-----------------------------------
Balance at Charged to Charged to Balance at
Beginning Costs and Other Accounts Deductions- End of
Description of Period Expenses -Describe(1) Describe(2) Period
- ---------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
AmeriSource Health
Corporation and
Subsidiaries
- -------------------------------------------------
Year Ended September 30,
1999
Allowance for doubtful
accounts............... $27,498,000 $6,956,000 $ -- $6,871,000 $27,583,000
=========== ========== ========== ========== ===========
Year Ended September 30,
1998
Allowance for doubtful
accounts............... $22,791,000 $9,990,000 $ -- $5,283,000 $27,498,000
=========== ========== ========== ========== ===========
Year Ended September 30,
1997
Allowance for doubtful
accounts............... $15,081,000 $6,705,000 $5,363,000 $4,358,000 $22,791,000
=========== ========== ========== ========== ===========
</TABLE>
- --------
(1) Reserves acquired in connection with the Walker Drug Company L.L.C.
acquisition in fiscal 1997.
(2) Accounts written off during year, net of recoveries.
S-4
<PAGE>
EXHIBIT 21
Subsidiaries of AmeriSource Health Corporation
As of December 1, 1999, the subsidiaries of AmeriSource Health
Corporation, together with their respective jurisdictions of incorporation, were
as follows:
Subsidiary Jurisdictions of Incorporation
---------- ------------------------------
AmeriSource Corporation Delaware
C.D. Smith Healthcare, Inc. Missouri
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINES SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FORM 10-K
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> SEP-30-1999
<PERIOD-START> OCT-01-1998
<PERIOD-END> SEP-30-1999
<CASH> 59,497
<SECURITIES> 0
<RECEIVABLES> 612,520
<ALLOWANCES> 27,583
<INVENTORY> 1,243,153
<CURRENT-ASSETS> 1,920,006
<PP&E> 134,740
<DEPRECIATION> 70,356
<TOTAL-ASSETS> 2,060,599
<CURRENT-LIABILITIES> 1,327,283
<BONDS> 558,705
0
0
<COMMON> 578
<OTHER-SE> 165,699
<TOTAL-LIABILITY-AND-EQUITY> 2,060,599
<SALES> 9,807,363
<TOTAL-REVENUES> 9,807,363
<CGS> 9,334,298
<TOTAL-COSTS> 9,334,298
<OTHER-EXPENSES> 314,063
<LOSS-PROVISION> 6,956
<INTEREST-EXPENSE> 39,690
<INCOME-PRETAX> 119,312
<INCOME-TAX> 48,397
<INCOME-CONTINUING> 70,915
<DISCONTINUED> 0
<EXTRAORDINARY> 3,449
<CHANGES> 0
<NET-INCOME> 67,466
<EPS-BASIC> 1.33
<EPS-DILUTED> 1.31
</TABLE>
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FORM 10-K
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
<S> <C> <C>
<PERIOD-TYPE> YEAR YEAR
<FISCAL-YEAR-END> SEP-30-1998 SEP-30-1997
<PERIOD-START> OCT-01-1997 OCT-01-1996
<PERIOD-END> SEP-30-1998 SEP-30-1997
<CASH> 90,344 0
<SECURITIES> 0 0
<RECEIVABLES> 509,130 0
<ALLOWANCES> 27,498 0
<INVENTORY> 954,010 0
<CURRENT-ASSETS> 1,558,526 0
<PP&E> 127,730 0
<DEPRECIATION> 59,775 0
<TOTAL-ASSETS> 1,726,272 0
<CURRENT-LIABILITIES> 1,093,032 0
<BONDS> 539,464 0
0 0
0 0
<COMMON> 582 0
<OTHER-SE> 74,773 0
<TOTAL-LIABILITY-AND-EQUITY> 1,726,272 0
<SALES> 9,503,037 8,298,635
<TOTAL-REVENUES> 9,503,037 8,298,635
<CGS> 9,041,140 7,894,499
<TOTAL-COSTS> 9,041,140 7,894,499
<OTHER-EXPENSES> 322,966 278,691
<LOSS-PROVISION> 9,990 6,705
<INTEREST-EXPENSE> 58,179 43,259
<INCOME-PRETAX> 80,752 82,186
<INCOME-TAX> 34,722 32,063
<INCOME-CONTINUING> 46,030 50,123
<DISCONTINUED> 0 0
<EXTRAORDINARY> 0 1,982
<CHANGES> 0 0
<NET-INCOME> 46,030 48,141
<EPS-BASIC> .92 .97
<EPS-DILUTED> .91 .96
</TABLE>
